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Nanoparticles have been pursued as a promising strategy to improve the safety and
therapeutic efficacy of systemic chemotherapy, but clinical translation of nanoparticle drug
carriers has been slow. Several reasons account for the tedious progress. From the formulation
perspective, drug loading efficiency and circulation stability remain to be improved: Low drug
loading increases the amount of co-delivered carrier materials, imposing biological burdens to
patients. Poor circulation stability compromises the pharmacokinetic benefits of nanoparticles.
To develop nanoparticles with high drug loading efficiency and circulation stability,
albumin-coated nanocrystal (“Abxtal”) formulation of hydrophobic anti-cancer drugs was
developed. Abxtal consists of drug nanocrystals and albumin coating, where albumin serves as a
stealth coating to reduce protein adsorption and a mediator of cellular uptake by cancer cells. When
Abxtal formulation for paclitaxel was compared with Abraxane® , an FDA-approved albuminpaclitaxel nanoparticle formulation, Abxtal showed superior anti-tumor efficacy at the equivalent
dose in a mouse model of B16F10 melanoma. A comparative pharmacokinetics/biodistribution
(PK/BD) study confirmed that the superior performance of Abxtal was due to its prolonged
circulation in blood and greater tumor accumulation relative to Abraxane.
Protein binding to surface of nanoparticles is another important factor that determines the
biological fate of the nanoparticles. When the effect of surface chemistry on the formation of
protein corona was studied, albumin coating provided protective effects against opsonization,
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consistent with the known role of albumin as a dysopsonin. The early difference in serum protein
binding led to differential macrophage uptake of nanocrystal, contributing to the superior in vivo
performance of Abxtal. Overall, the improved therapeutic efficacy of Abxtal is attributable to its
higher circulation stability and dysopsonin function of albumin, resulting in preferential tumor
accumulation.
Furthermore, the broad utility of Abxtal formulation as an enabling formulation for
hydrophobic small molecule drugs was demonstrated with docetaxel and carfilzomib. Abxtal
formulation of docetaxel entered drug-resistant NCI/ADR-RES ovarian cancer cells by
interactions with albumin-receptors, showing the potential utility in the treatment of multidrugresistant tumors. Abxtal formulation of carfilzomib protected the drug from enzymatic degradation,
leading to enhanced bioavailability relative to the solvent- or cyclodextrin-solubilized
formulations.
In tandem with the robust nanoparticle platform development, the utility of nanoparticles
in immune checkpoint blockade therapy has been explored. Specifically, it is envisioned that
nanoparticle delivery of the chemotherapeutic that functions as immunogenic cell death inducer
will synergize with immune checkpoint blockade. The underlying hypothesis is that nanoparticles
will help immune checkpoint blockade therapy by (i) improving the delivery of immunogenic cell
death inducers; (ii) altering the cellular uptake mechanism and intracellular stress; (iii) creating,
binding and retaining neo-antigens in situ and delivering them to antigen presenting cells; and (iv)
co-delivering immune adjuvants. Preliminary studies were performed to determine their ability to
induce immunogenic cell death. The release of damage-associated molecular patterns from
B16F10 melanoma cells treated with different nanoparticle formulations was examined as in vitro
measures of immunogenic cell death induction.
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In summary, this dissertation demonstrates how simple changes in physical assembly of
the components in formulation can affect PK/BD profiles of a drug and improve therapeutic
efficacy of the drug. Furthermore, the utility of nanoparticles in immune checkpoint blockade
therapy is presented to achieve durable and complete remission of cancer.
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INTRODUCTION

1.1

Needs for new drug delivery systems in systemic delivery of anticancer drugs
A critical challenge in systemic chemotherapy is the toxicity due to their non-specific

distribution, which limits the maximum tolerated dose of an anti-cancer drug. To reduce the
toxicity of chemotherapy, nanotechnology-based drug delivery systems, such as polymeric
nanoparticles, lipid-based formulations, and polymer conjugates, are used as vehicles of anticancer drugs [1, 2].
Nanoparticles have several advantages over free drugs. The formulations of hydrophobic
drugs typically contain solubilizers. For example, paclitaxel (PTX), a chemotherapeutic used in
the therapy of lung, ovarian, and breast cancers [3], is solubilized in a mixture of polyoxyethylated
castor oil and ethanol (50:50), which are associated with serious side effects [4]. Encapsulation in
biocompatible polymers or lipids eliminates the needs for toxic solubilizers and helps disperse the
water-insoluble drug, improving the therapeutic index [1]. Similarly, liposome formulation of
docetaxel increased the maximum tolerated dose by more than three times compared to Taxotere® ,
a drug solution formulation of docetaxel with polysorbate 80 and dehydrated alcohol [5].
In addition, NPs can improve pharmacokinetics (PK) and biodistribution (BD) [6, 7]. For
example, low-density lipoprotein-resembling nanoparticle of paclitaxel showed more than 3-fold
higher blood area under the curve and lower toxicity in human patients as compared to Taxol® [8].
Liposomal docetaxel extended the circulation half-life from minutes to hours compared to
Taxotere [9, 10]. NPs can protect the drug against degradation and achieve favorable PK with
reduced toxicity.
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For example, a liposome formulation increased the half-life and the blood AUC of
gemcitabine by 8 times compared to Gemzar® (drug solution formulation) in a mouse model [7]
(Figure 1).

Figure 1. Biodistribution of [5-3H] gemcitabine administered as a free form (A) or entrapped in
unilamellar PEGylated liposomes (B) in immunodeficient NOD-SCID mice bearing human
anaplastic thyroid xenograft tumors as a function of time. Reprinted with permission from [7].
Copyright 2010 Elsevier.
1.2

Nanomedicine: the state of art

1.2.1 Clinical benefits of nanoparticles revisited
Despite

decades-long

history

of

nanoparticle-based

approaches,

numerous

nanotechnology-based formulations have fallen short of the promise and been slow to reach the
bedside [11]. By changing BD of small molecule chemotherapeutics, nanoparticles improve their
safety profiles; however, they do not necessarily increase therapeutic efficacy of unit drug. For
example, Genexol-PM® (mean paclitaxel dose 246.8 ± 21.3 mg/m2), polymeric micelle
formulation of paclitaxel, did not demonstrate patient survival benefit over conventional solution
formulation, Genexol® (mean paclitaxel dose 168.3 ± 10.6 mg/m2), the surfactant-solubilized
formulation of paclitaxel [12] (Figure 2).
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Figure 2. Overall survival of metastatic breast cancer patients who received either polymeric
micelle formulation of PTX (Genexol-PM® ; mean PTX dose 246.8 ± 21.3 mg/m2) or Cremophor
EL PTX formulation (Genexol® ; mean PTX dose 168.3 ± 10.6 mg/m2). The number of survived
patients during the follow-up is shown in the bottom. No significant difference in overall
survival was observed between treatment groups. Adapted with permission from [12]. Copyright
2017 Korean Cancer Association.
Also, the meta-analysis of clinical trials of liposomal formulation revealed no significant
difference in the overall survival when compared to non-liposomal formulation [13] (Figure 3).
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Figure 3. Meta-analysis of clinical studies. Overall survival in patients treated with liposomal
versus conventional chemotherapy formulations. Reprinted with permission from [13].
Copyright 2016 Elsevier.
The lack of therapeutic benefits in human patients and slow clinical translation indicate a
deficiency in our understanding of nanoparticle design and development. Therefore, the
fundamental assumptions for nanoparticles needs to be re-examined.
1.2.2 The enhanced permeability and retention (EPR) effect: the Golden Gate for NP entry to
tumors
The concept of enhanced permeability and retention (EPR) effect for nanomedicine began
with an observation in 1986 [14]. When intravenously introduced, polystyrene-co-maleic acidhalf-butylate copolymer conjugated with neocarzinostatin (SMANC) preferentially accumulated
in the tumor by non-covalently binding with albumin in vivo. In addition, Evans blue, which also
forms complex with albumin, demonstrated slow clearance from the tumor relative to normal
tissue. This observation indicates that tumor tissues exhibit unique characteristics compared to
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normal tissues: porous tumor vasculature and reduced lymphatic drainage, termed the EPR effect.
Therefore, circulating nanoparticles cannot penetrate healthy tissues with tightly-joined
endothelium but selectively extravasate through porous tumor vasculature, and will be retained in
the interstitium due to defective lymphatic drainage, leading to accumulation at the tumor tissue
(Figure 4). Since the discovery of the EPR effect, it has become the governing principle of
nanomedicine delivery to tumors.

Figure 4. Targeting tumor cells using nanocarriers of anti-cancer agents. Schematic illustration of
the EPR effect allowing extravasation of nanomedicines through the hyperpermeable tumor
blood vessels and their accumulation at the tumor site. Nanomedicines cannot penetrate normal
intact blood vessels as found in healthy tissues Reprinted with permission [15]. Copyright 2013
Springer Nature.
1.2.3 Limitations of the EPR effect
Many researchers have developed sophisticated nanocarriers to exploit the EPR effect in
solid cancers by optimizing physicochemical properties of nanoparticles, including size, surface
charge, and shape. However, according to a provocative meta-analysis, the efficiency of
nanoparticle delivery to tumor is still limited, accounting for 0.7% of administered dose at most
[16], so the purported advantage of nanoparticles is not demonstrated. In line with this observation,
some have questioned the validity of the EPR effect as a reliable feature of tumors [17, 18].
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Another challenge of the EPR effect is the heterogeneity. For example, breast cancer
patients are often classified into distinct sub-types based on the cancer-specific receptor expression
level. Likewise, the degree of EPR effects varies among patients. For example, the degree of
vascularization varies with tumor types and correlates well with tumor accumulation of

111

In-

labled PEGylated liposomes. In other words, nanoparticles can utilize the EPR effect in highly
angiogenic tumors [19] (Figure 5). Furthermore, a large variability in tumor uptake was found
within same tumor type (e.g. from 2.7% to 53% injected dose/kg).

Figure 5. Effect of estimated tumor volume on the uptake of radiolabeled liposomes in patients
with SCCHN, lung, and breast cancers. Tumor volume was estimated from clinical or
radiographic measurement. Reprinted with Permission from [19]. Copyright 2001 American
Association for Cancer Research.
1.2.4 Physicochemical limitations of nanomedicine
Current development and design of nanoparticles do not efficiently leverage the EPR effect
due to the poor physicochemical limitations. Many sophisticated approaches aim to exploit cancerspecific features at the cellular level (e.g. receptor expression, level of enzymes). However, in vivo
fate of nanoparticles relies more heavily on their long circulation to reach the target site and their
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integrity at arrival. If these features are not met, advantage of nanoparticle-based delivery is lost
regardless of the ligand design. Therefore, low drug loading and circulation instability should not
be overlooked.
1.2.4.1 Low drug loading
One main drawback of current nanotechnology-based delivery systems in the clinical
application is relatively low drug loading, typically less than <20 wt% for hydrophobic drugs [16].
The low drug loading means that a high dose of non-drug materials will be administered to achieve
an active drug concentration. Non-drug materials are generally chosen judiciously with
consideration of biocompatibility and degradability, but their biological and long-term effects are
not always predicted in the early stage of development because a limited number of doses are given
over a short period of time. Slowly degrading or non-degrading materials can accumulate over
multiple doses, which become an increasing biological burden to patients [20, 21].
In addition, administration of a large dose of carrier materials can compromise the colloidal
stability of nanoparticles because concentrated nanoparticles can irreversibly aggregate and be
subject to clearance by the mononuclear phagocyte system (MPS), negatively affecting their
bioavailability. Low drug loading also necessitates increased injection volume and/or and higher
concentration of nanoparticles, which can be a dose limiting factor [16, 22]. Low drug loading also
has a negative impact on the commercialization of the formulation due to higher manufacturing
cost and scale-up difficulties [23].
1.2.4.2 Circulation instability
When tested in buffers, drugs may seem to remain stable in nanoparticles and release
slowly. However, in physiological media containing proteins and lipids, nanoparticles often
release drugs much faster than in buffers, losing most of the payload in a couple of hours [24]

8

(Figure 6). When this happens in blood, nanoparticles cannot retain drug in circulation and do not
provide benefits over drug solution formulation, such as favorable PK profiles and cellular
interactions. In this case, the formulation mainly functions as a solubilizer of drug. Nanoparticle
instability is a significant problem in vivo, although often underestimated in vitro.

Figure 6. Release kinetics of paclitaxel loaded nanoparticle in media containing phosphate buffer
saline (PBS), fetal bovine serum (FBS), or Tween 80. PTX/NPs equivalent to 4.4 μg PTX were
suspended in 1 mL of release medium (PBS, Tween/PBS, or FBS/PBS) and incubated at 37 °C
with constant agitation. After separating NP pellets, the sampled supernatant was analyzed.
Adapted with permission from [24]. Copyright 2015 American Chemical Society.
1.2.4.3 Protein corona
Upon administration into the bloodstream, nanoparticle’s surface is covered by proteins,
forming the “protein corona”. The protein corona alters the surface property of nanoparticles,
defining their biological identity distinct from synthetic identity [25, 26] (Figure 7). To understand
the physiological interactions of nanoparticles with biomolecules and cells and their in vivo fate,
characterization of protein corona specific is important corona [27]. For example, apolipoprotein
E and B-100 were shown to promote transport of nanoparticles to brain [28]. Immunoglobulins
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and complement proteins enhances monocyte uptake [29]. In addition, non-specific protein
adsorption on silica nanoparticles also interferes with the targeting proteins in the corona [30].

Figure 7. Relationship between the synthetic identity, the biological identity and the
physiological response of liposomes in a physiological environment. When covered by a “protein
corona” in vivo, a new particle biological identity emerges that is ultimately responsible for the
physiological response. Reprinted with permission from [25]. Copyright 2011 Royal Society of
Chemistry.
Therefore, the protein corona has direct implications in nanoparticle-mediated drug delivery.
It can enhance cellular uptake of nanoparticles by making it easier to access receptors on target
cells or inhibit the uptake by masking the targeting ligand of interest. For example, Salvati et al
demonstrated that transferrin-targeted silica nanoparticles could not selectively target A549 lung
cancer cells in the presence of serum in the media [31]. Similarly, Baier et al showed that cellular
uptake of polystyrene nanoparticles by HeLa cells was reduced by adsorption of bovine serum
albumin [32]. In addition, protein corona can hinder the drug release from mesoporous silica
nanoparticles by obstructing pores [33] or decrease the colloidal stability of nanoparticles by
causing agglomeration [34].
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1.3

Approaches to overcome the current limitations in nanomedicine
Current challenges in clinical translation of nanomedicine may be overcome by judicious

selection of patient population who can benefit from the nanomedicine and optimal design of
nanoparticles that can effectively leverage the EPR effect.
1.3.1 Patient selection
Clinical trials of nanomedicine should be designed considering the diversity of cancers [35,
36], because nanoparticles are not expected to work effectively when tumor does not exhibit the
EPR effect. Only selected patients, who will likely to show the EPR effect (e.g. tumor
vascularization and permeability), should receive nanoparticle-based therapeutics for the effective
clinical trials. Treatment regimens may be stratified by the patient’s status with the use of
appropriate biomarkers of the EPR effect. For example, Miller et al. have demonstrated that the
tumor distribution of pre-administered magnetic nanoparticle functions as a surrogate marker for
the EPR effect, allows stratification of treatment groups, and predicts tumor delivery of docetaxel
encapsulated PLGA-PEG nanoparticles [37] (Figure 8).

Figure 8. (A) Tumor progression in HT1080 tumors ranked according to low, medium, and high
magnetic nanoparticle uptake in tumor. (B) In orthotopic 4T1 breast cancer tumors, MNP
prediction of polymeric nanoparticle-encapsulated docetaxel delivery in tumor. (C) MNP
prediction of unencapsulated solvent-docetaxel accumulation. Reprinted with Permission from
[37]. Copyright 2015 American Association for the Advancement of Science.
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Likewise, dosing schedule of nanoparticle formulation has to be optimized taking
consideration of pharmacokinetic changes between patients, rather than using weight-based dosing
that fits all types of patients [38]. The efforts of understanding heterogeneity of cancer will
ultimately allow tailoring nanoparticle behavior, addressing a key challenge in clinical translation
of nanoparticles.
1.3.2 Nanocrystallization: An approach to increase drug loading
To address the limited drug loading efficiency, a group of poorly water-soluble drugs have
been formulated into small crystalline particles called nanocrystals (NC) [39] (Figure 9) . Since
they are entirely made from drug itself, nanocrystals can achieve the highest drug loading up to
100% [40]. The nanocrystals can remain stable in aqueous media and serve as nanoparticles with
the sufficient lattice energy between drug molecules [41]. With optimized processing methods,
solid particles ranging from 100 nm to 300 nm are formed in water. Typical processing methods
include “top down” (large particles are broken down by high shear stress), “bottom up” (nucleation
of drug molecules are induced by solvent and temperature conditions), or combinations of the two
[39, 42].
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Figure 9. Basic structures of polymeric nanoparticles, nanoemulsions, solid lipid nanoparticles
(SLN), nanostructured lipid carriers (NLC), and drug nanocrystals (NC). Reprinted with
permission from [39]. Copyright 2011 Elsevier.
Due to high drug loading efficiency, nanocrystals have drawn great amount of interest as a
way to deliver poorly water-soluble anticancer drugs. However, in case of paclitaxel, none of
nanocrystal systems has shown superior antitumor effects compared to commercial paclitaxel
formulations, such as Taxol (surfactant-solubilized paclitaxel) and Abraxane (albumin-bound
paclitaxel) at equivalent doses [43-45]. Therefore, the therapeutic benefit of nanocrystal
formulations remains questionable, and I hypothesize the shortcomings are due to suboptimal
surface properties of nanocrystals.
1.3.3 Nanocrystallization and physicochemical modifications: An approach to increase
circulation stability
Due to high lattice energy between drug molecules, nanocrystals can remain stable in
aqueous media and serve as strategy to increase circulation stability nanoparticles [41, 46, 47]. The
lattice energy larger than solvation energy will impart nanocrystals with lower apparent solubility
and dissolution rate compared to amorphous solid counterpart [48]. Surface coating can further
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modulate the dissolution of nanocrystals. For example, layer-by-layer assembly of polyelectrolytes
reduced the dissolution rate of paclitaxel [49]. Nanocrystals are relatively resistant to enzymatic
instability as the degradation is limited to the outermost surface of particle [50, 51].
Physicochemical strategies are also employed in other nanoparticle systems to improve
circulation stability. For example, in polymeric micelles (PM), premature drug release from
polymeric micelles has been main culprit for low efficiency in vivo [52]. To overcome the
limitations, the polymers can be tailored to optimize intermolecular interactions with drug cargo
(e.g. π-π.stacking interactions with doxorubicin, or coordination interaction with cisplatin).
Covalent entrapment of drugs via hydrazine- or disulfide bond also controlled the release rate [53].
However, this approach needs to be tailored to accommodate the inherent physicochemical
properties of individual drug compound.
1.3.4 Albumin coating: An approach to further improve biodistribution of nanocarriers
Unfunctionalized nanocrystals are easily removed by the mononuclear phagocyte system
due to opsonization of hydrophobic surfaces in the plasma [54, 55]. Polyethylene glycol or other
hydrophilic surfaces help reduce the mononuclear phagocyte system uptake of nanocrystals, but
they can interfere with the retention and intended cellular interactions after nanocrystal distribution
in tumors [56]. In addition, PEGylated nanomedicine has been associated with generation of PEGspecific antibody, which leads to a rapid elimination of subsequent treatments [57]. To address
these challenges, serum albumin was used for surface functionalization of nanocrystals.
Albumin is the most abundant protein in plasma involved in transendothelial transport of
nutrients and drugs [58]. As a native protein with a long circulation half-life, albumin bound to
hydrophobic nanoparticles can prevent their opsonization and phagocytosis [59, 60]. Moreover,
many tumors have a high demand for albumin as a major source of energy and nutrients, and,
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therefore, an increased capacity to take up albumin [61] (Figure 10). Albumin can extravasate not
only by paracellular pathway but also via transcellular pathway that involves gp60 (albondin) [58].
Once in tumors, albumin can bind to SPARC (secreted protein acidic and rich in cysteine)
expressed in various cancer cells and tumor interstitium [62] (Figure 11). Based on these features,
albumin modification will help nanocrystals to avoid mononuclear phagocyte system uptake,
translocate across the tumor endothelium, and retain in tumor.

Figure 10. Tumor uptake of a residualizingly radiolabeled rat serum albumin ([111In] DTPARSA) after 3 days. More than 25% of the injected dose of albumin was trapped by a Walker-256
carcinosarcoma, seeded at the left hind leg of Sprague Dawley rats. The color code grading for
increasing amounts of radioactivity was blue, green, yellow, followed by red. Reprinted with
permission from [61]. Copyright 1997 Elsevier.
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Figure 11. Uptake of albumin-drug nanoparticles is presumably mediated by the gp60
transcytosis pathway and subsequent binding to SPARC in the tumor extracellular matrix.
Reprinted with permission from [62]. Copyright 2011 Elsevier.
In addition, additional considerations are necessary for using albumin as surface coating
regarding the protein conformation. The surface of nanoparticles may influence conformation
changes in the protein’s folding status upon adsorption, which implicates downstream proteinprotein interactions and immune recognition [63] (Figure 12).
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Figure 12. Schematic representation of NP surface induced unfolding of the interacting protein
molecule and consequences. (A) Protein molecules adsorb on to the NP surface. (B) NP surface
may induce conformational change to the native structure of the adsorbed protein molecule,
causing it to unfold. Such protein conformational changes may either (C) alter the function of the
native protein, or even lead to (D) exposure of “cryptic” epitopes which may result in
immunological recognition of the complex. Reprinted with permission from [63]. Copyright
2013 BioMed Central Ltd.
As a dysopsonin, surface-bound albumin may also influence the formation of protein
corona in bloodstream [64]. Therefore, the correlation of serum protein binding and various surface
chemistry of nanocrystals will be investigated.

1.4

Nanoparticles as an adjuvant in cancer immunotherapy
Even with optimally designed nanoparticles, chemotherapy alone often fails to achieve

complete remission of cancer, but only prolongs survival by few days/weeks at most in the preclinical studies [65] (Figure 13). In other words, tumors mostly relapse after cessation of treatments.
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Figure 13. Typical examples of tumor growth (a) and survival time (b) after i.v. administration of
solution and different nanoparticle formulations. Reprinted with permission from [65]. Copyright
2013 Springer Nature.
When the goal of cancer therapy is to achieve complete and durable remission,
chemotherapy alone has inherent limitations. In this regard, immunotherapy with immune
checkpoint inhibitors seems promising, but the response rate is limited to 20-40% of patients
because many tumors lack lymphocyte infiltration [66]. Nanoparticles can play significant roles in
improving immunogenicity of tumor, thereby extending benefits of immunotherapy.

1.5

Summary
Systemic delivery of anticancer drug by nanotechnology-based approach is a compelling

therapeutic option, but the clinical translation is hampered for various reasons. Due to complexity
and heterogeneity of tumor biology, the patients for nanoparticle-based treatment need to be
judiciously chosen to fully take advantage of nanotechnology-based system. More importantly,
many have overlooked the essential physicochemical properties of nanoparticles, high drug
loading and good circulation stability.
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1.6

Specific Aims
I aim at overcoming the identified challenges by developing albumin-coated

nanocrystallization (Abxtal) method. The developed system features high drug loading and high
serum stability, which will reduce the nanoparticle dose requirement and effectively leverage the
EPR effect. This strategy offers significant therapeutic benefits to the practice of systemic
chemotherapy.
1.6.1 Specific Aim 1. To develop and evaluate Abxtal formulation of paclitaxel vs. Abraxane®
Abxtal formulation of paclitaxel (PTX) was developed, physicochemical properties
characterized, in vitro cellular interactions with macrophages and melanoma cancer cells evaluated,
and in vivo antitumor efficacy compared with that of Abraxane. In order to further elucidate the
underlying mechanisms for in vivo behaviors, PK/BD profiles of Abxtal and Abraxane were
compared.
1.6.2 Specific Aim 2. To evaluate of the effect of NC surface chemistry on the formation of
protein corona
To understand the relationship between the chemical identity of nanoparticles and the
protein adsorption to their surface, protein corona formation and serum protein binding kinetics
were studied using nanocrystals with different surface chemistry.
1.6.3 Specific Aim 3. To apply Abxtal formulation to other hydrophobic drugs
Other hydrophobic drugs, docetaxel and carfilzomib, were formulated with Abxtal, and the
effects on cellular interactions and metabolic stability of drugs were studied to demonstrate the
broad applicability of Abxtal formulation.
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1.7

Organization of Chapters
The following thesis is presented in five Chapters. Chapter 2 describes development

process of Abxtal formulation of paclitaxel, its physicochemical characterizations, and in vitro
evaluations for with macrophages and melanoma cancer cells. The preliminary in vivo anti-tumor
effect study with Abraxane is presented. Chapter 3 presents comparative PK/BD profiles of Abxtal
and Abraxane and anti-tumor study at the maximum tolerated dose. In addition, the serum protein
corona analysis and binding kinetic studies are investigated to correlate with in vivo behaviors of
Abxtal. Chapter 4 describes Abxtal formulation development processes for other hydrophobic
drugs, docetaxel and carfilzomib, along with their in vitro evaluations. In Chapter 5, the potential
utility of nanoparticles in immune checkpoint blockade is discussed. Finally, the dissertation and
my perspectives in the field of nanoparticle-based cancer therapy are discussed in Chapter 6.
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DEVELOPMENT OF ALBUMIN-COATED
NANOCRYSTAL (ABXTAL)

2.1

Introduction
Due to the high drug content and stability, nanocrystals have been considered promising for

systemic delivery of poorly soluble small molecule drugs. However, nanocrystals have limitations
in controlling particle size and surface properties. With conventional approaches (top-down and
bottom-up methods), it is challenging to reduce particle size below 200 nm, the upper limit of
preferential extravasation in the permeable tumor vasculature [1, 2]. In addition, bare nanocrystals
with hydrophobic surface are prone to non-specific protein adsorption and thus readily taken up
by the MPS [3, 4]. Hydrophilic surface like PEG helps reduce the MPS uptake of nanocrystals, but
PEGylation can compromise the intended cellular interaction with a tumor cell surface, resulting
in lower cellular uptake [5]. For example, paclitaxel nanocrystals formed with PEGylated
paclitaxel did not show better antitumor effects than Abraxane® , a clinical benchmark formulation
of paclitaxel at the equivalent dose (Figure 14) [6].
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Figure 14. In vivo antitumor efficacy. Tumor volume change of MDA-MB-231/luc bearing nude
mice after being treated with Taxol, Abraxane, PTX-NCs, or PEG-PTX-NCs. For each animal,
five consecutive doses were given (marked by arrows). Data represent mean ± SD (n = 6). **p <
0.001 vs. control group, ##p < 0.05 vs. PTX-NC group. Reprinted with permission from [6].
Copyright 2015 Royal Society of Chemistry.
To address these challenges, nanocrystal was prepared by transforming an amorphous
mixture of paclitaxel and Pluronic F127 into crystalline particles [7] and covering with serum
albumin. The surface albumin is also expected to improve the delivery of nanocrystals to tumors
by dysopsonin properties [8], interaction with gp60 on the endothelium [9] and SPARC in the
tumor interstitium [10], and tumors’ high demand for albumin as a major energy source and
nutrients [11]. Other nanoparticle systems using albumin for similar purposes indicate that the
surface of nanoparticles, especially hydrophobic and charged surface, induces structural changes
of albumin, which compromises its stealth function, destabilizes nanoparticles and causes
aggregation [12, 13]. For example, high temperature above 55˚C during nanoparticle synthesis
compromised intracellular delivery of nanoparticles by disrupting the secondary structure of
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albumin [14]. Therefore, native conformation of albumin needs to be preserved for the intended
functions.
In this study, nanocrystals with different sizes and incipient surfaces for albumin binding
were produced, and their cellular interactions were compared to investigate the effect of the size
and the status of surface-bound albumin. The best nanocrystal form was compared with Abraxane
with respect to the dissolution behavior and in vivo antitumor activities.

2.2

Development of Abxtal for paclitaxel
Abxtal for paclitaxel was prepared in two steps: crystallization in surfactant-containing

medium [7], followed by surface coating with albumin (Figure 15). In a dry film, the surfactant
making contacts with drug molecule as an amorphous mixture (Figure 16). Two types of
surfactants, Pluronic F127, a non-ionic surfactant, and hexadecyltrimethylammonium bromide
(CTAB), a cationic surfactant, were used. paclitaxel transforms to crystalline particles during
hydration (Figure 16), and the surfactant starts to dissolve, adsorbs to the nanocrystal surface via
hydrophobic domain, and exposes the hydrophilic domain to water. Therefore, surfactants at the
interface between the incipient and water effectively limits the crystal growth and agglomeration
[7]. The incipient nanocrystal were called Cim-F (Crystallized in medium containing F127) and
Cim-C (Crystallized in medium containing CTAB) according to the type of surfactant included in
the film.
In the second step, the incipient nanocrystals were coated with albumin. The final forms of
nanocrystals were called Cim-F-alb (Cim-F stabilized with albumin) and Cim-C-alb (Cim-C
stabilized with albumin). For comparison, nanocrystals with bare surface were prepared by the
anti-solvent and low temperature-induced crystallization method [2], and was called PNC
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(paclitaxel nanocrystal). After albumin coating, the formed nanocrystals were called PNC-alb
(PNC stabilized with albumin).

Figure 15. Schematic description of Cim-F-alb preparation

Figure 16. X-ray powder diffraction patterns of a dry film of F127, a dry film of PTX and F127
mixture, and Cim-F-alb.
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2.3

Characterizations: composition, morphology, size, and surface charge
The paclitaxel contents in PNC-alb, Cim-C-alb, and Cim-F-alb were 88.5 ± 4.2wt% (n=4),

79.2 ± 5.1wt% (n=4), 88.7 ± 2.5wt% (n=4), respectively. The albumin contents were 7.6 ± 1.4wt%
(PNC-alb), 14.8 ± 0.7wt% (Cim-C-alb), and 9.7 ± 0.9wt% (Cim-F-alb). The amount of remaining
F127 and CTAB were not directly measured, but according to the mass balance their contents were
estimated to be 1-6wt%. Removal of excess surfactants was important for potential safety issues.
F127 has been reported to produce hypercholesterolemia in mice after single intraperitoneal (IP)
injection of 500 mg/kg [15] and to induce reversible change in the renal filtration capacity in rats
at IP injection of 1000 mg/kg [16]. CTAB is also reported to be cytotoxic in HT-29 colon cancer
cells [17] and HeLa cervical cancer cells [18].
With transmission electron microscopy (TEM) images, all NCs showed a long rod shape
(Figure 17). PNC-alb showed a rod shape with a length of 254.7 ± 119 nm and a width of 76.5 ±
21 nm (n = 172). Cim-C-alb and Cim-F-alb showed a higher aspect ratio with smaller widths. CimC-alb had an average length of 342.5 nm ± 132 nm and a width of 33.5 ± 7 nm (n = 195), while
Cim-F-alb had a length of 198.4 ± 80 nm and a width of 35.8 ± 6 nm (n = 188). The rod shape is
beneficial for systemic drug delivery by helping avoid uptake by the MPS [19]. Also, the prismatic
morphology agrees with the crystalline nature of nanocrystals (Figure 16).
When measured by dynamic light scattering (DLS), Cim-F-alb had the smallest z-average
(235.6 ± 36.5 nm), and Cim-C-alb and PNC-alb were similar (351.9 ± 75.3 nm and 358.9 ± 79.6
nm). The size of Cim-F-alb could be further reduced by adjusting the duration of hydration.
Decreasing duration of hydration from 15 min to 5 s produced smaller particles with a z-average
of 196.7 ± 34.6 nm, which accelerated its dissolution (Supplementary Figure 1). The dependence
of particle size on the hydration time indicates that nanocrystals grew during the hydration step
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whereas the subsequent sonication step helped perturb the nanocrystal growth. Cim-F-alb was also
lyophilized and reconstituted to the original size with trehalose as a cytoprotectant (Supplementary
Figure 2).
Interestingly, the zeta potential of NC did not correlate with the amount of surface-bound
albumin (Supplementary Figure 3). With an isoelectric point of pH 4.7, greater amount of surfacebound albumin expects to result in more negative surface charge at pH 7.4. On the other hand,
Cim-C-alb had similar zeta potential as PNC-alb, while Cim-C-alb contained twice amount of
albumin of PNC-alb. Also, Cim-F-alb was not as negatively charged as PNC-alb, while their
albumin contents were comparable. We hypothesized that the conformation and arrangement of
surface-bound albumin may differ based on the surface property it binds and investigated the status
of surface-bound albumin. Additional non-albumin proteins other than albumin were identified on
the surface of nanocrystals, particularly Cim-C-alb, which was attributed to the cationic surface of
Cim-C (Supplementary Figure 4).

Figure 17. TEM images and size analysis. Length and width of NCs from randomly selected
TEM images were analyzed with ImageJ. Scale bars: 500 nm.
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2.4

Evaluation of the status of surface-bound albumin
Typical methods for assessment of protein conformation, such as circular dichroism and

synchronous fluorescence spectroscopy, were not suitable for analyzing the surface-bound
albumin because nanocrystals showed optical interference with the measurements. Therefore, we
resorted to pulse proteolysis for evaluating the status of albumin bound to nanocrystals [20]. The
principle of pulse proteolysis is that folded and unfolded proteins have different susceptibilities to
proteolysis for a short time. Accordingly, the extent of protein unfolding can be estimated based
on the degree of digestion by non-specific proteases. Cim-C-alb showed the highest degree of
digestion (67.8 ± 13.4%), and PNC-alb and Cim-F-alb showed similar digestion of 18.4 ± 7.2%
and 14.5 ± 2.6%, respectively (Figure 18a). This indicates that albumin on Cim-C-alb was more
unfolded than those of PNC-alb and Cim-F-alb.
The functional status of albumin in related to conformation change can also be estimated by
evaluating its esterase-like activity [21, 22]. When the ability of albumin to hydrolyze pnitrophenylacetate to p-nitrophenol was measured, PNC-alb and Cim-F-alb showed similar %
active albumin, but Cim-C-alb showed much lower % active albumin (Figure 18b). Consistent
with the proteolysis assay, albumin on Cim-C-alb underwent greater conformation change than
PNC-alb and Cim-F-alb.
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Figure 18. (a) % Digestion of albumin after pulse proteolysis. % digested albumin was defined as
(1-albumin band intensity after proteolysis / albumin band intensity prior to proteolysis) × 100. n
= 4 independently and identically performed experiments. (b) % Active albumin content estimated
by esterase assay. % active albumin was calculated by dividing esterase active albumin / the
amount of albumin determined by SDS-PAGE. n = 3 independently and identically performed
experiments. *: p < 0.01 by Tukey's multiple comparisons test.
2.5

Effect of albumin status in the cellular interactions of Abxtal
Because the surface-bound albumin is expected to mediate the nanocrystal-cell interactions,

cellular uptake of nanocrystals was tested with J774A.1 murine macrophages and B16F10
melanoma cells, which represent the MPS and cancer cells overexpressing SPARC [23],
respectively.
In J774A.1 macrophages, Cim-C-alb was taken up significantly more than PNC-alb and
Cim-F-alb (Figure 19). Lower cellular uptake of Cim-C-alb at low temperature indicated that CimC-alb uptake was energy-dependent endocytosis. Also, when macrophages were pre-treated with
polyinosinic acid, a known inhibitor of scavenger receptor-mediated endocytosis [24], cellular
uptake of Cim-C-alb was reduced to the same level as other nanocrystals, implying denatured
albumin on Cim-C-alb preferentially taken up by macrophages via scavenger receptors. On the

33

other hand, PNC-alb and Cim-F-alb with more native albumin avoided the scavenger receptormediated endocytosis by macrophages.

Figure 19. (a) PTX uptake by J774A.1 macrophages after 30 min incubation with PNC-alb, CimC-alb, and Cim-F-alb (equivalent to 30 μg/mL PTX) at 4˚C or 37˚C. n = 3 independently and
identically performed experiments. (b) PTX uptake by J774A.1 macrophages after 30 min
incubation with PNC-alb, Cim-C-alb, and Cim-F-alb (equivalent to 30 μg/mL PTX) with and
without pre-treatment of polyinosinic acid. n = 4 independently and identically performed
experiments. *: p < 0.05; **: p < 0.01; #: p < 0.001 by Sidak's multiple comparisons test.
Nanocrystal uptake by B16F10 melanoma cells showed different trend. Cellular uptake was
highest with Cim-F-alb and least with Cim-C-alb (Figure 20). Consistent with the cellular uptake,
Cim-F-alb treatment induced greater cell death and lower metabolic activity in B16F10 cells than
PNC-alb and Cim-C-alb. The preferential uptake of Cim-F-alb by B16F10 cells is attributed to the
native conformation and arrangement of the surface-bound albumin, which facilitates its
interaction with SPARC expressed on B16F10 cells. Compared to PNC-alb, greater uptake of CimF-alb is likely attributable to its smaller size. The absence of potential cytotoxicity due to F127
was confirmed in B16F10 at a concentration up to 1 mg/mL (Supplementary Figure 6).
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Figure 20. (a) PTX uptake by B16F10 melanoma cells after 3 h incubation with PNC-alb, CimCalb, and Cim-F-alb (equivalent to 30 μg/mL PTX). (b-c) Cytotoxicity of NC in B16F10 cells
measured after 3 h incubation with NC and 21 h additional incubation in treatment-free medium,
measured by propiodium iodide staining and flow cytometry (b) and MTT assay (c). n = 3
independently and identically performed experiments (a, b). n = 5 measurements (c). *: p < 0.05
by Tukey's multiple comparisons test.
To confirm the involvement of albumin in cellular uptake of Cim-F-alb, Cim-F (incipient
nanocrystals prepared without albumin coating) and Cim-F-alb were compared for their cellular
uptake by B16F10 cells (Figure 21a). Cellular uptake was greater with Cim-F-alb than Cim-F,
confirming the contribution of albumin to cellular uptake process. Also, the presence of ≥ 20
mg/mL albumin inhibited the Cim-F-alb uptake by B16F10 cells, indicating Cim-F-alb and
albumin share the same receptor (Figure 21b). This specific concentration of albumin is higher
than typical albumin concentration in tissue interstitium [25], so the interstitial albumin will not
significantly compromise the cellular interaction of Cim-F-alb. At the same time, the possibility
that some tumors have higher level of interstitial albumin than normal tissues and may negatively
impact cellular uptake of Cim-F-alb cannot be excluded. Meanwhile, albumin on Cim-F-alb rather
helps reduce macrophage uptake of the nanocrystals. When evaluated by confocal microscopy,
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colocalization of Cim-F-alb with lysosome (Pearson’s correlation coefficient of 0.71) was
observed (Supplementary Figure 11), indicating trafficking of Cim-F-alb to late endo/lysosomes
(Figure 21c). Also, the cellular uptake of Cim-F-alb was completed abolished at 4 ˚C
(Supplementary Figure 10), so the uptake occurs via energy-dependent endocytosis pathway.
Rhodamine B was chosen as a fluorescence marker because the dye maintained constant
fluorescence intensity at a pH range of 5 to 7, suitable for the intracellular imaging (Supplementary
Figure 7). Also, the rhodamine B-doped nanocrystals showed comparable size and shape as nonlabeled counterpart (Supplementary Figure 8). In addition, the rhodamine B signal was shown to
represent nanocrystals, not dye leached out of the nanocrystals by comparing with covalently
labeled nanocrystals (Supplementary Figure 9).

Figure 21. (a) PTX uptake by B16F10 cells after 3 h incubation with Cim-F or Cim-F-alb
(equivalent to 30 μg/mL PTX). n = 3 independently and identically performed experiments; *: p
< 0.01 by unpaired two-tailed t-test. (b) PTX uptake by B16F10 cells after 3 h incubation with
Cim-F-alb (equivalent to 30 μg/mL PTX) in the presence of extra albumin. n = 3 independently
and identically performed experiments; *: p < 0.01 by Tukey's multiple comparison test vs. no
albumin control. (c) Intracellular localization of rhodamine B doped Cim*-F-alb in B16F10 cells
after 3 hours incubation. Green = lysosome, blue = nuclei, and red = rhodamine B. Scale bar =
10 μm.
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2.6

High serum stability of Abxtal
For the prediction of in vivo fate of Abxtal, particle dissolution was monitored using light

scattering method [26], which exploits the linear relationship between the number of particles
and absolute scattering intensities. The dissolution of Cim-F-alb in PBS and undiluted FBS was
evaluated in comparison with Abraxane over 24 h at 37°C (Figure 22).

Figure 22. Derived count rate of Cim-F-alb and Abraxane in PBS (top) and undiluted FBS
(bottom) at 37 °C. For samples in FBS, the values were obtained by subtracting the derived
count rate of FBS from those of particle suspensions in FBS at each time point. n = 3
independently and identically performed experiments.
For Abraxane, the linearity of scattering intensity vs. concentration plot started to
disappear as soon as in 1 h, indicating that the dissolution occurred quickly. The solubility of
Abraxane in FBS (75 μg/mL) was similar to that of amorphous paclitaxel (Supplementary Figure
12) in FBS (71.9 μg/mL) (Figure 23). In contrast, Cim-F-alb maintained the linear pattern in
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FBS, with slight decrease in the slope attributable to partial dissolution of paclitaxel (no greater
than 8.3 ± 3.0 μg/mL, Figure 23). This suggests that amorphous status Abraxane (Supplementary
Figure 13) in blood will dissociate into albumin-bound paclitaxel molecules at paclitaxel <75
μg/mL, whereas Cim-F-alb in blood will mostly remain as nanoparticles at least for 24 h.

Figure 23. (a) Amorphous as-received PTX dissolved in undiluted FBS, 50% FBS/PBS, and 10%
FBS/RPMI after 6 h incubation at 37 °C. (b) Abraxane and Cim-F-alb dissolved in undiluted
FBS after 6 h incubation at 37 °C. The measured values represent the sum of serum proteinbound and free PTX.
Considering typical paclitaxel dose in mice is 15-40 mg/kg and the blood volume is 1.5-2.5
mL [27], the initial paclitaxel concentration is estimated to be 120-530 μg/mL. In this
concentration range, Cim-F-alb is likely to circulate as nanoparticles, whereas most of Abraxane
will dissociate instantaneously into individual albumin molecules bound to paclitaxel. In other
words, during the initial circulation and biodistribution phase, Cim-F-alb and Abraxane will
circulate in different forms – nanoparticles and paclitaxel-bound albumin molecules,
respectively. This is consistent with the literature, where Abraxane is reported to dissociates into
individual paclitaxel-bound albumin molecules upon dilution in bovine serum albumin solution
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[28]. The predicted in vivo behavior of Abxtal in mice will be similar in case of humans. Based
on the typical clinical dose of Abraxane (1.9 m2 body surface area, 125 mg/m2 dose, and 5L
blood volume in human), the expected blood paclitaxel concentration is approximately 48
μg/mL, which is lower than the measured paclitaxel solubility of Abraxane, but higher than that
of Cim-F-alb. When Abraxane, Cim-F-alb, and solvent-dissolved paclitaxel were evaluated for
the comparative cytotoxicity, all three groups showed similar response curves, indicating Cim-Falb will provide similar effects as free drug when dissolved (Supplementary Figure 14).

2.7

In vivo activity of Abxtal vs. Abraxane
To test if paclitaxel circulating as nanoparticles will have any advantages over Abraxane in

antitumor effects, Cim-F-alb and Abraxane were administered to C57BL/6 mice bearing
subcutaneous B16F10 tumors. Cim-F-alb is uniquely suited for the test because Cim-F-alb
consists of the same components as Abraxane (albumin and paclitaxel), but differs from
Abraxane in the circulation stability. This allows to exclude the potential contribution of the
carrier materials [29].
Cim-F-alb or Abraxane (paclitaxel equivalent to 15 mg/kg) was administered by tail vein
injection on days 0, 3, 6, and 9, and tumor growth was monitored. Cim-F-alb was well tolerated
and no significant loss of body weight was observed. Abraxane did not attenuate the growth of
B16F10 tumors as compared to PBS control, while Cim-F-alb delayed tumor growth (Figure 24).
When the specific growth rate, which is more appropriate in assessing the exponential growth of
tumor [30], was compared, the Cim-F-alb group showed a significantly lower specific growth
rate than the PBS- or Abraxane-treated groups (p < 0.05 vs. both groups, Tukey’s multiple
comparisons test).
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Figure 24. In vivo activity of Cim-F-alb and Abraxane in B16F10 tumor bearing C57BL/6 mice.
(a) Box-and-whisker plot of B16F10 tumor volumes: The box extends from the 25th to 75th
percentiles, the line in the middle of the box indicates the median, and the whiskers go down to
the smallest value and up to the largest. Mice were treated with PBS (black; n =6), Abraxane
(blue; n = 6), or Cim-F-alb (red; n = 7) at 15 mg/kg q3d × 4. Arrows indicate treatment times.
One mouse in each of the Abraxane and PBS group was sacrificed on day 7 due to the large size
of the tumor. (b) Specific growth rate of B16F10 tumor = ΔlogV/Δt (V: tumor volumes; t: time
in days). Horizontal bars = means. *: p < 0.05 by Tukey's multiple comparisons test.
To compare the effect of treatment on the tissue level, tumors collected one day after the
last dose were analyzed with respect to the number of apoptotic cells and the paclitaxel content
(Figure 25). Tumor sections from the Cim-F-alb group showed a significantly higher number of
terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end (TUNEL)positive apoptotic cells than those of PBS- or Abraxane-treated groups (Supplementary Figure
15, Supplementary Figure 16). Consistently, the paclitaxel content in tumor was significantly
higher in the Cim-F-alb group (27.4 ± 22 μg/g) than in the Abraxane treatment group (13.8 ± 6
μg/g).
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Figure 25. (a) Representative photographs of terminal deoxynucleotidyl transferase-mediated
deoxyuridine triphosphate nick end (TUNEL)-stained B16F10 tumor sections. (b) Quantitative
analysis of TUNEL-stained sections. % apoptotic cells = number of apoptotic cells / total number
of nuclei measured by ImageJ. Data are represented as averages and standard deviations of 12
images for PBS- and Abraxane groups and 14 images for Cim-F-alb group (2 images from each
tumor section). *: p < 0.01 by Tukey's multiple comparisons test. (c) PTX content in B16F10
tumor tissues. n = 6 for Abraxane and n = 7 for Cim-F-alb group. Horizontal bars= means. *: p <
0.05 by Mann-Whitney test.
Taken together, these results support that Cim-F-alb circulating as nanoparticles have
reached tumors better than Abraxane which dissociates into paclitaxel-bound albumin molecules
upon intravenous injection. To further investigate if the superior performance of Cim-F-alb
relative to Abraxane was due to preferable cellular uptake of the nanocrystals, their cellular
uptake in macrophages and B16F10 cells were compared (Figure 26). In J774A.1 murine
macrophages, no significant difference in cellular uptake between two groups was observed,
which is attributable to their small size to avoid phagocytic uptake. On the other hand, Cim-F-alb
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uptake was lower than Abraxane in B16F10 cells, likely due to the advantage of molecularly
dispersed Abraxane in entering cells relative to nanoparticulate Cim-F-alb. Therefore, the
advantage of Cim-F-alb over Abraxane is not at the cellular level, but likely at their
pharmacokinetics and biodistribution profiles.

Figure 26. Uptake of Abraxane and Cim-F-alb by (a) J774A.1 macrophages and (b) B16F10
melanoma cells. Cim-F-alb and Abraxane (eq. to 30 μg PTX/mL) were incubated with J774A.1
cells for 30 min or with B16F10 cells for 3 h at 37 °C. Data are presented as averages and
standard deviations of 3 independently and identically performed experiments. *: p < 0.05 by
unpaired t-test.
2.8

Conclusion
Abxtal for the systemic delivery of paclitaxel, Cim-F-alb, was developed with surface

stabilization with native albumin. The small size and native conformation of surface-bound
albumin in Cim-F-alb resulted in reduced uptake by J774A.1 macrophages and increased uptake
by SPARC-positive B16F10 melanoma cells. In a mouse model of B16F10 melanoma, Cim-Falb outperformed Abraxane at the equivalent dose. The in vitro dissolution study suggests that
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the superior performance Cim-F-alb is likely due to the circulation stability of nanoparticles,
which will be verified in the subsequent PK/BD studies.

2.9

Experimental

2.9.1 Materials
Paclitaxel was a gift of Samyang Biopharm (Seoul, Korea). Pluronic F127 (F127) was a
gift from BASF (New York, NY, USA). Abraxane was obtained from Celgene Corporation
(Summit, NJ, USA). Human serum albumin (≥96% agarose gel electrophoresis) and
hexadecyltrimethylammonium bromide (CTAB) were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Reagents for sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
were purchased from Bio-Rad (Hercules, CA, USA). Terminal deoxynucleotidyl transferase dUTP
nick end labeling kit (DeadEnd Fluorometric TUNEL System) was purchased from Promega
(Madison, WI, USA). All other reagents were purchased from Sigma-Aldrich (St. Louis, MO,
USA).
2.9.2 Nanocrystal production
Nanocrystals were prepared in two steps: crystallization in surfactant-containing medium,
followed by surface coating with albumin. The first step followed the method described by Liu et
al. [7] with modification. Briefly, a mixture of paclitaxel and surfactant (6 mg paclitaxel and 24
mg Pluronic F127 or 2.4 mg of CTAB) was fully dissolved in 3 mL of chloroform in a roundbottom flask. Chloroform was evaporated with a rotary evaporator at 40 °C for 10min to form a
thin film on the wall of the flask. Six milliliters of distilled water was added to the film at room
temperature. The formed incipient nanocrystals were called Cim-F (Crystallized in medium
containing F127) and Cim-C (Crystallized in medium containing CTAB), according to the type of
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surfactants included in the film. The paclitaxel/surfactant film was hydrated for 5 s to 15 min with
bath sonication, and the hydrated suspension was probe-sonicated in an ice-water bath for 5 min
with a power level of 40% and a 1:1 duty cycle every 2 s.
In the second step, the NC were stabilized with albumin. Four milligrams of albumin was
added to 1 mL of nanocrystal suspension (equivalent to 1 mg paclitaxel) and incubated at room
temperature for 24 h on a rotating rocker. The nanocrystal suspension was centrifuged at 135,700
rcf for 10 min at 4 °C to remove excess surfactant and unadsorbed albumin. The pellet was
resuspended in water and collected by centrifugation at 135,700 rcf for 10 min at 4 °C. The formed
NC were called Cim-F-alb (Cim-F stabilized with albumin) and Cim-C-alb (Cim-C stabilized with
albumin).
For confocal microscopy, Cim-F-alb was labeled with Rhodamine B (Cim*-F-alb) by
adding 0.1 mg/mL of aqueous rhodamine B solution in the film hydration step. The amount of
incorporated rhodamine B was measured based on fluorescence intensity (λex/λem: 540 nm/625 nm)
of Cim*-F-alb dissolved in acetonitrile (ACN).
For comparison, nanocrystals were also prepared by the anti-solvent and temperatureinduced crystallization described in the literature[2]. Briefly, 1 mL of 4 mg/mL paclitaxel/ethanol
solution was added to 20 mL of distilled water and stirred for 10 min in a round-bottom flask
immersed in an ice water-filled sonication bath. Ethanol was removed by 10 min rotary
evaporation at 40 °C. Nanocrystals were collected on a polycarbonate membrane filter with an
average pore size of 100 nm and retrieved in distilled water by 1 min bath sonication. The formed
nanocrystals were called PNC. To form an albumin-coated PNC (PNC-alb), albumin was added to
PNC suspension (equivalent to 1 mg/mL pacltiaxel) to make 4 mg/mL and incubated at room
temperature for 24 h on a rocking shaker. PNC-alb was washed in the same way as above.
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2.9.3 Nanocrystal characterization
2.9.3.1 Particle size
The particle size of NC was measured in sodium phosphate buffer (1 mM, pH 7.4) with a
Zetasizer Nano-ZS90 (Malvern Instruments, Westborough, MA, USA). The particle size was
measured at each step of preparation (hydration, albumin coating, and washing).
2.9.3.2 Particle morphology
The morphology of nanocrystals was examined with a Phillips CM-100 transmission
electron microscopy (Hillsboro, OR, USA). Samples were mounted on a 400-mesh Cu grid with
Formvar/carbon supporting film and stained with 2% phosphotungstic acid. Images were captured
with a SIA L3-C2megapixel CCD camera (Scientific Instruments and Application, Duluth, GA).
2.9.3.3 X-ray powder diffraction
Cim-F-alb and its intermediate were analyzed with a Rigaku Smartlab™ diffractometer
(Rigaku Americas, Texas, USA) with a Cu-Kα radiation source and a highly sensitive D/tex ultra
detector. The powders were placed in glass sample holders, and powder patterns were obtained
from 5 to 40° 2θ at a scan speed of 4°/min and a step size of 0.02°. The voltage and current used
were 40 kV and 44 mA, respectively.
2.9.3.4 Paclitaxel content
The paclitaxel content in nanocrystals was determined by HPLC. Nanocrystals with a
premeasured mass were dissolved in a 50:50 mixture of ACN and water at a concentration of 30–
60 μg/mL and filtered with 0.45 μm syringe filter prior to analysis. HPLC was performed with an
Agilent 1100 HPLC system (Palo Alto, CA), equipped with Ascentis C18 column (25 cm × 4.6
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mm, particle size: 5 μm). The mobile phase was a 50:50 mixture of water and ACN and run at 1
mL/min. Paclitaxel was detected by a UV detector at a wavelength of 227 nm.
2.9.3.5 Albumin content and status
The albumin content in nanocrystals was determined with SDS-PAGE. NC with a
premeasured mass or standard albumin solutions were mixed with 4× Laemmli sample buffer and
heated at 95 °C for 5 min. The samples were resolved in a 12% polyacrylamide gel. The gel was
stained with QC Colloidal Coomassie Stain (Bio-Rad) and imaged with Azure C300 (Dublin, CA,
USA). The albumin bands were quantified by densitometry function of the AzureSpot Analysis
Software (Dublin, CA, USA). The albumin content was determined by comparing the band
intensities of nanocrystal samples and standard albumin solutions.
The status of the nanocrystal-bound albumin was analyzed by pulse proteolysis[20]. PNCalb, Cim-C-alb, and Cim-F-alb (eq. to 0.2mg/mL albumin) were treated with 0.2 mg/mL of
thermolysin in HEPES buffer (pH 7.4, 20mM) containing 100mM NaCl and 10mM CaCl2. After
5min incubation at room temperature, 5 μL of 50mM EDTA was added to a 15 μL aliquot to
quench proteolysis. For the control, nanocrystals were treated the same without thermolysin. The
treated NC was mixed with 4× Laemmli sample buffer and heated at 95 °C for 5 min. The samples
were resolved in 15% polyacrylamide gel and detected with QC Colloidal Coomassie Stain. The
protein bands were imaged with Azure C300 to analyze the extent of proteolysis of surface-bound
albumin. The percent digestion was calculated as (1-the band intensity of albumin after proteolysis/
the band intensity of albumin prior to proteolysis) × 100.
The functional status of nanocrystal-bound albumin was estimated based on its esterase
activity [31]. PNC-alb, Cim-C-alb, and Cim-F-alb (eq. to 0.5mg/mL albumin) in sodium phosphate
buffer (pH 7.4, 0.2M) was incubated with 100 μM of p-nitrophenyl acetate (pNPA) at room

46

temperature. Immediately and 60 min after the addition of pNPA, a supernatant was separated
from the nanocrystal suspension by centrifugation and read at 405 nm to quantify p-nitrophenol
(product of pNPA hydrolysis). The amount of active albumin was calculated based on the rate of
pNPA hydrolysis. The percent active albumin was calculated as the amount of active albumin
divided by the amount of total albumin determined with SDS-PAGE.
2.9.4 Cellular uptake of nanocrystals
B16F10 mouse melanoma cells (ATCC, Manassas, VA, USA) were grown in DMEM
medium containing 10% fetal bovine serum (FBS) and penicillin (100 IU/mL) and streptomycin
(100 μg/mL). Cells were seeded in a 6well plate at a density of 100,000 cells per well. After
overnight incubation, the cell culture medium was replaced with fresh medium, to which 100 μL
of PNC-alb, Cim-C-alb, or Cim-F-alb in PBS was added to provide the final concentration
equivalent to 30 μg/mL paclitaxel.
After incubation with the treatments for 30 min (J774A.1) or 3 h (B16F10), cells were
washed with PBS two times to remove unbound nanocrystals. The cells in each well were then
collected in 1 mL of PBS. A 30 μL fraction of the cell suspension was analyzed with a flow
cytometer to determine the cell count. The rest was analyzed to determine Paclitaxel taken up by
the cells. Briefly, the cell pellet was lysed with 3 cycles of freezing and thawing, followed by probe
sonication. The cell lysate was extracted with ethyl acetate, and the content of paclitaxel in the
ethyl acetate phase was analyzed with HPLC. Carbamazepine (CBZ) was used as an internal
standard during the extraction.
For J774A.1 macrophages, the same experiment was repeated at 4°C or after pre-treatment
with polyinosinic acid. When the experiment was performed at 4°C, the macrophages were
equilibrated at 4 °C for 30 min prior to the nanocrystal treatment. When polyinosinic acid was
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used, the macrophages were preincubated with 100 μg/mL of polyinosinic acid in serum-free
medium for 30 min, washed once with PBS, and treated with nanocrystals in serum-free medium
for 30 min. Intracellular paclitaxel content was determined as described above.
For B16F10 cells, the same experiment was repeated with and without albumin (5–50
mg/mL) in serum free medium.
2.9.5 Intracellular localization of Cim-F-alb
Cim*-F-alb uptake by B16F10 cells was observed with confocal microscopy. B16F10 cells
were seeded in a 35-mm dish with a glass window (MatTek) at a density of 50,000 cells per dish.
After 24 h, the medium was replaced with fresh medium, and the cells were incubated with
LysoTracker Green DND-26 (25 nM) for 30 min. After washing, cells were incubated with Cim*F-alb or Cim#-F-alb (30 μg/mL paclitaxel eq.) or free rhodamine B solution (0.3 μg/mL) for 30
min in complete medium. Following two washes with PBS, the cells were fixed with 4%
paraformaldehyde in PBS for 10 min. After 5 min nucleus staining with Hoechst 33342 (2 μg/mL),
the fixed cells were imaged with a Nikon A1R confocal microscope. Hoechst and LysoTracker
Green DND-26 were detected with λex/λem of 407 nm/425–475 nm and 488 nm/500–550 nm,
respectively. Cim*-F-alb or free Rhodamine B was detected with λex/λem of 561 nm/570–620 nm.
2.9.6 Dissolution of Cim-F-alb in PBS and FBS
Based on the linear relationship between the number of particles and light scattering
intensity [26], the derived count rate (i.e., absolute light scattering) was monitored as a measure of
particle dissolution in PBS or undiluted FBS. Cim-F-alb and Abraxane equivalent to paclitaxel 25100 μg/mL were incubated in PBS or FBS at 37 °C for 24 h with periodical measurements of their
derived count rates using a Zetasizer Nano-ZS90. Each measurement was done for 2 runs at 2 s,
at the measurement position of 4.65mm and with an attenuator setting of 10.
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2.9.7 Anti-tumor activity
All animal procedures were approved by Purdue Animal Care and Use Committee, in
conformity with the NIH guidelines for the care and use of laboratory animals. Eight to ten week
old male C57BL/6 mice were obtained from Envigo (Indianapolis, IN, USA) and acclimatized for
1 week prior to the procedure. Each mouse received a subcutaneous injection of 106 B16F10
melanoma cells in the upper flank of the right hind leg.
When the tumor was palpable (12 days after tumor cell inoculation), the animals were
randomly assigned to 3 groups (n = 6 for PBS and Abraxane-treated group, n = 7 for Cim-F-alb
group) and treated with 4 tail vein injections of PBS, Abraxane, or Cim-F-alb (equivalent to 15
mg/kg of paclitaxel in 100 μL per injection) at 3-day interval. Abraxane and Cim-F-alb were
prepared in sterile PBS freshly on the day of treatment. Tumor volume and body weights were
monitored every day. The length (L) and width (W) of each tumor were measured with a digital
caliper, and the volume (V) was calculated according to the modified ellipsoid formula: V = (L ×
W2)/2. Specific growth rate of a tumor was calculated as ΔlogV/Δt (t: time in days) [30]. One day
after the last injection, mice were sacrificed for the tumor tissue analysis. The excised tumors were
fixed in 10% neutral buffered formalin solution or frozen at −80 °C until analysis. Animals losing
weight in excess of 20% body weight or with tumors reaching >10% body weight were humanely
euthanized prior to the end of the study.
The frozen tumors were homogenized in PBS using a Omni Tissue Master 125
homogenizer (Kennesaw, Georgia, USA). One milliliter of the homogenate was mixed with 3 mL
of ethyl acetate with 35 μg of carbamazepine as an internal standard and rotated for 1 h for
paclitaxel extraction. After centrifugation at 3724 rcf for 10 min, 2.8 mL of ethyl acetate layer was
evaporated and dissolved in a 1:1 mixture of ACN/water for HPLC analysis.
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The fixed tumor tissues were embedded in paraffin, sectioned, and mounted on a glass slide
for TUNEL assay (DeadEnd Fluorometric TUNEL system; Promega). Images were taken with a
Nikon A1R confocal microscope. Two randomly selected fields per tissue were analyzed with
ImageJ (National Institutes of Health, Bethesda, MD) to count apoptotic cells and nuclei. Percent
apoptotic cells were calculated as the ratio of the number of apoptotic cells to the number of the
nuclei.
2.9.8 Statistical analysis
All statistical analysis was performed with GraphPad Prism 6. All in vitro data were
analyzed with one-way or two-way ANOVA test to determine the difference of means among
groups, followed by Tukey's or Sidak's multiple comparisons test. In vivo data were analyzed with
one-way ANOVA, followed by Tukey's multiple comparison test unless specified otherwise. A
value of p < 0.05 was considered statistically significant.
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EVALUATION OF PHARMACOKINETICS AND
BIODISTRIBUTION OF ABXTAL

3.1

Introduction
The study described in Chapter 2 led us to believe that the advantage of Cim-F-alb over

Abraxane in the antitumor efficacy is due to favorable PK. Due to crystalline status, Cim-F-alb
will circulate as nanoparticles in the blood, while amorphous Abraxane falls apart as paclitaxelbound albumin molecules. To test this hypothesis, I examined PK/BD profiles of Cim-F-alb and
Abraxane.
Expecting that paclitaxel nanocrystals would exhibit favorable PK/BD profiles than
commercial formulations of paclitaxel, such as Taxol (surfactant-solubilized paclitaxel) and
Abraxane (albumin-bound paclitaxel), several groups evaluated PK/BD profiles of nanocrystal
formulations [1-5]. Typical paclitaxel nanocrystals were prepared with an average size ranging
from 150 to 250 nm by high-pressure homogenization or antisolvent precipitation. With no surface
protection, these nanocrystals however showed rather unfavorable PK/BD profiles, such as a
shorter plasma t1/2, less systemic exposure, greater accumulation in the MPS organs [5], and lower
tumor accumulation than paclitaxel injectable solutions [4]. Surface stabilizers such as polymeric
surfactants or proteins were used to protect the nanocrystals from opsonin adsorption and MPS
recognition and/or to increase target specificity [1-3], but the outcomes have been equivocal.
Paclitaxel nanocrystals stabilized with Pluronic F127 and docusate sodium did not enhance the
systemic exposure of paclitaxel, but rather increased the liver and spleen accumulation [2].
Paclitaxel nanocrystals with a layer-by-layer polyelectrolyte assembly and polyethylene glycol
(PEG) layer on the surface showed higher accumulation in the MPS organs and lower tumor
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accumulation than Abraxane, due to the premature loss of PEG surface and subsequent
opsonization [1] (Figure 27).

Figure 27. Tumor tissue distribution after injection of Abraxane and NC/PSS70-(PLR/PSS17)3PEG. a) PTX concentration in g) tumor (n = 4-7). B) Desorption of PLL-g-PEG-sulfo-Cy5 from
NC/PSS70-(PLR/PSS17)3-PEG after incubation in PBS or mouse serum at 37 °C (n=3). Adapted
with permission from [1]. Copyright 2016 Wiley-VCH.
In addition, nanocrystal systems reported so far have not shown an improved antitumor
efficacy as compared to commercial paclitaxel formulations at the equivalent dose [3, 6-8].
Paclitaxel nanocrystals stabilized with Pluronic polymers were not significantly better than Taxol
in delaying tumor growth [8, 9]. When transferrin (Tf)-coated paclitaxel nanocrystals were used
to treat Tf-receptor-expressing KB tumors [6], their performance was better than bare nanocrystals
(tumor growth suppression rate 45.1% vs 28.8%) but not superior to Taxol’s (tumor growth
suppression rate 93.3%). Paclitaxel nanocrystals coated with PEG via covalent conjugation
improved the stability of surface protection, but their anticancer efficacy was not significantly
better than those of Abraxane and Taxol [7]. In most cases, the main advantage of nanocrystal
systems was limited to eliminating the use of toxic solubilizers rather than improving the
therapeutic efficacy of unit dose.
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In this chapter, PK/BD profiles of Cim-F-alb and Abraxane were compared to examine the
impact of the circulation stability and albumin coating on tumor deposition and long-term
anticancer efficacy of the nanocrystals. Also, the protein binding on surface of nanocrystals, called
“protein corona”, was studied using nanocrystals with different surface chemistries to correlate
with in vivo results of nanocrystal.

3.2

Pharmacokinetic and biodistribution profiles of Abxtal vs. Abraxane
In the previous chapter, Cim-F-showed superior antitumor efficacy in B16F10 tumor-

bearing mice compared to Abraxane at paclitaxel dose of 15 mg/kg q3d × 4. With identical
components (paclitaxel and albumin), Cim-F-alb and Abraxane were speculated to have different
structural stability in circulation, where Cim-F-alb circulates as nanoparticles and Abraxane
circulates as individual paclitaxel-bound albumin molecules. To test this hypothesis, the PK/BD
profiles of Cim-F-alb and Abraxane were studied. We first determined the maximum tolerated
dose (MTD) for Cim-F-alb with healthy C57BL/6 mice as paclitaxel 30 mg/kg q3d × 5
(Supplementary Figure 17), where neither significant body weight change nor outstanding
abnormality in blood chemistry was found (Supplementary Table 2). This was comparable to
maximum tolerated dose of Abraxane reported in the literature (Supplementary Table 1) [10].
For comparison of the PK profiles, a single intravenous injection of Cim-F-alb or Abraxane
at paclitaxel 30 mg/kg dose was given to C57BL/6 mice (Figure 28). The plasma paclitaxel
concentration-time profiles indicated higher paclitaxel concentrations with Cim-F-alb than with
Abraxane, especially at later time points (beyond 6 h post-injection). The terminal t1/2 in plasma
following the dosing of Abraxane was 3.7 h, comparable to the values reported in other studies
with mouse models and similar analytical methods [1, 11]. The t1/2 of Cim-F-alb was 5.6 h,
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approximately 1.5 times longer than that of Abraxane. The PK parameters obtained via noncompartmental analysis also indicated an enhanced systemic exposure of paclitaxel with Cim-Falb. The total area under the plasma concentration–time curve (AUC0-∞) of Cim-F-alb was 1.7
times greater than Abraxane. Accordingly, the total clearance with Cim-F-alb was slower than that
with Abraxane. On the other hand, the volume of distribution at steady state (Vss) and mean
residence time were increased with Cim-F-alb by 1.6 and 2.8 times, respectively, compared to
Abraxane. These PK parameters indicate that Cim-F-alb offers an extended circulation time and
drug target residence time, likely due to slower dissolution of crystalline Cim-F-alb than Abraxane,
which disintegrates quickly upon intravenous injection [11-13].

Figure 28. Pharmacokinetics of Cim-F-alb and Abraxane after single dose intravenous injection
(PTX equivalent to 30 mg/kg) by tail vein in B16F10 tumor bearing C57BL/6 mice. n =3 per
each time point for Abraxane (blue) and Cim-F-alb (red). Non-compartmental analysis was
performed to estimate the PK parameters. PTX content in plasma was determined by LC-MS.
The biodistribution of Cim-F-alb and Abraxane was also consistent with the PK result
(Figure 38). When tumor tissues were harvested and analyzed at various time points post-injection,
the paclitaxel levels were higher with Cim-F-alb than with Abraxane, at all time points compared.
The peak paclitaxel levels in tumor tissues were observed at 6 h post-injection: 2.3 ± 1.2% and 0.5
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± 0.2% of the injected dose for Cim-F-Alb and Abraxane, respectively. In the liver and spleen, the
paclitaxel levels were highest immediately after the injection, but a clear second peak was observed
at 6 h post-injection. Although their intensities were relatively small, the second peaks were also
apparent in the lung, kidney, and heart in mice that received Cim-F-alb, but not in mice that
received Abraxane. The second peaks observed with Cim-F-alb suggest that the major organs
receive not only an initial deposition but also a delayed input from the stable Cim-F-alb particles
in circulation. With its circulation stability, Cim-F-alb likely afforded advantage over Abraxane in
leveraging the enhanced permeability of tumors, thus achieving a high level of paclitaxel in tumors.
These results underscore the significance of physical stability in efficient delivery of circulating
NPs to tumors. Notwithstanding, other nanocrystal formulations with presumably similar stability
in circulation did not demonstrate favorable PK/BD profiles compared to commercial paclitaxel
formulations [1, 2, 4, 5]. Therefore, these results suggest that the surface-bound albumin layer on
Cim-F-alb also contributed to its efficient delivery to tumors.
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Figure 29. Biodistribution of Cim-F-alb and Abraxane after single dose intravenous injection (PTX
equivalent to 30 mg/kg) by tail vein in B16F10 tumor bearing C57BL/6 mice. n =3 per each time
point for Abraxane (blue) and Cim-F-alb (red). PTX content in each tissue was determined by LCMS.
3.3

Serum protein binding to nanocrystals
Adsorption of serum proteins, in particular those tagging foreign subjects for phagocytic

removal (opsonization), is the first challenge for the intravenously injected nanoparticles to
encounter in circulation [14-16] (Figure 30). To examine whether the albumin coating affected the
extent and kinetics of opsonization, we prepared paclitaxel nanocrystals with different surface
properties (Cim-F-alb with albumin coating, PNC with no protective coating, Cim-C-alb with
denatured albumin coating, or Cim-C with cationic surfactant layer and no albumin), incubated

58

them in undiluted mouse serum, and analyzed the surface-adsorbed proteins (protein corona) by
LC-MS/MS. In addition, in situ interaction between serum proteins and nanocrystals was
monitored by biolayer interferometry (BLI).

Figure 30. The synthetic and biological identity of nanoparticles. When nanoparticles are injected
intravenously, blood proteins bind to the surface and form a protein corona. The proteins bound to
the surface provide the nanoparticles with a biological identity, which changes their interactions
with cells, biological barriers and the body. Reprinted with permission from [16]. Copyright 2014
Royal Society of Chemistry.
3.3.1 Protein corona analysis
Cim-F-alb and PNC were incubated in C57BL/6 mouse serum for 15 min or 3 h. The
nanocrystals were washed twice to remove loosely bound proteins (soft corona) leaving only the
proteins adsorbed to nanocrystal surface with high affinity (hard corona) (Supplementary Figure
18). The serum-incubated nanocrystals showed minor or negligible changes in the particle size:
the z-average of Cim-F-alb increased from 207.9 ± 15.2 nm to 246.0 ± 17.9 nm after the incubation
(n = 3), and that of PNC from 385.1 ± 28.4 nm to 372.5 ± 29.5 nm (n = 3). On the other hand, both
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nanocrystals showed greater negative surface charges indicating the adsorption of serum proteins:
the zeta potential of Cim-F-alb changed from −9.4 ± 0.8 mV to −19.9 ± 0.6 mV after the incubation,
and that of PNC from −4.0 ± 1.4 mV to −22.6 ± 0.4 mV (Supplementary Figure 19).
Proteomic analysis via LC-MS identified α-/β-globins and lipoproteins such as Apo E, Apo
A-IV, and Apo A-I to be mainly bound to the nanocrystals, but detected no outstanding differences
between Cim-F-alb and PNC (Figure 31). Another nanocrystal with denatured albumin coating,
Cim-C-alb, also did not show significant difference in protein corona composition. When
evaluated with SDS-PAGE band profiles for rough estimation of the extent and composition of
protein adsorption, no notable difference in corona composition was observed among three
nanocrystals (Supplementary Figure 20). Previous studies reported the formation of distinct
protein corona on nanoparticles according to the surface chemistry [17-19] and identified specific
proteins in the corona responsible for various cellular interactions or the lack thereof. Clusterin is
reported to be crucial to the stealth effect of polystyrene nanoparticles [20]. Pre-coating of
polystyrene nanoparticles with Apo A-I reduced the uptake by murine macrophages [17]. Other
apolipoprotein proteins (Apo A-IV and Apo C-III) also reduce nonspecific cellular interaction of
polystyrene nanoparticles when present on the surface [21]. On the other hand, Apo E is involved
in endocytosis of nanoparticles by the brain endothelial cells and thus helps deliver nanoparticles
to the brain [22]. Complement component C3 promotes the interaction with macrophage
complement receptors and accelerates the removal of nanoparticles [23]. Since most studies have
been performed with inorganic nanoparticles, such as gold [19], silica [24, 25], or polymeric
nanoparticles [17, 26], these observations may not be directly applicable to Cim-F-alb, which has
a relatively “soft” surface (i.e., non-covalently bound albumin).
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Moreover, the hard corona analysis is highly dependent on consistent isolation of the
surface-bound proteins [27] and, thus, subject to interexperimental variability, as we have
experienced. This procedure also precludes the identification of soft corona proteins, whose role
in nanoparticle function is poorly understood due to the rapid exchange with serum components
and the difficulty in separation and identification [28-30]. To test if the albumin surface affected
initial soft corona formation, we resorted to an alternative method to monitor protein binding in
situ.

Figure 31. Protein corona on PNC, Cim-C-alb, and Cim-F-alb measured by LC-MS/MS
proteomics analysis. PNC, Cim-C-alb, and Cim-F-alb were incubated in mouse serum for 15 min
or 3 h. % total adsorbed protein was calculated using the percentage molecular weight
normalized spectral count (MWNSC).

61

3.3.2 Serum protein binding kinetics
The short-term interactions between nanocrystals and mouse serum proteins were
evaluated by real-time evaluation of nanocrystal binding to serum proteins using biolayer
interferometry (BLI) (Figure 32). BLI detects molecules adsorbed to a fiber optic biosensor
according to the changes in optical interference between reflected beams [31, 32]. Serum proteins
were immobilized to the tip of a biosensor and exposed to nanocrystal suspensions for 5 min to
monitor their interaction with nanocrystals. The equilibrium dissociation constant (KD) values
were much smaller with PNC than with Cim-F-alb: PNC (KD1 = 5.16 × 10−6 M, KD2 = 0.0079 ×
10−6 M) and Cim-F-alb (KD1 = 1300 × 10−6 M, KD2 = 8620 × 10−6 M) (Supplementary Table 3).
These results demonstrate a much higher affinity of PNC for serum proteins than that of Cim-Falb, most likely due to the hydrophobic nature of PNC surface. Cim-C with cationic surface charge
and no albumin coating showed even greater binding affinity for serum proteins (KD1 = 0.49 × 10−6
M, KD2 = 2.56 × 10−6 M) than PNC, indicating electrostatic interactions with negatively charged
proteins. This shows that albumin on Cim-F-alb created a hydrophilic, protein-resistant layer,
consistent with its known role as a dysopsonin [33, 34]. It is noteworthy that this difference
between Cim-F-alb and PNC was not reflected in the hard corona profiles (Figure 31), implying
that the surface albumin mainly affects the formation of soft corona in the initial circulation phase
(Supplementary Figure 21).
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Figure 32. Binding of PNC, Cim-C, and Cim-F-alb to mouse serum proteins immobilized to a
fiber optic biosensor, determined by biolayer interferometry (BLI). a) PNC, b) Cim-C, and c)
Cim-F-alb. Black: raw sensorgram data; red: curve fit of sensorgram by a 2:1 heterogeneous
ligand model. Dotted vertical line separates the association and dissociation phase. Each curve
indicates different NC concentrations: 235 × 10−6 to 15 × 10−6 M (top to bottom) for PNC and
Cim-F-alb. 23.5 × 10−6 M to 367 × 10−9 M (top to bottom) for Cim-C.
3.3.3 Implications of serum proteins in cellular interactions of nanocrystals
To investigate if the soft corona takes part in phagocytic removal of nanocrystals, we
incubated Cim-F-alb or PNC with J774A.1 murine macrophages in 50% mouse serum (allowing
in situ corona formation) or in serum-free culture medium (no protein corona) for 0.5 h and
evaluated the nanocrystal uptake. More PNC was taken up by J774A.1 macrophages in the medium
containing 50% serum than those in serum-free medium, suggesting that the corona formed in 0.5
h facilitated their uptake (Figure 33). On the other hand, macrophage uptake of Cim-F-alb was not
affected by 50% serum in 0.5 h. This demonstrates that Cim-F-alb was resistant to the initial corona
formation, consistent with the results from biolayer interferometry analysis. It is worth noting that
the particle uptake profiles were more favorable for Cim-F-alb than PNC. Cim-F-alb and PNC
with or without hard corona were incubated with J774A.1 macrophages or B16F10 melanoma cells.
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Cim-F-alb was taken up less by macrophages and more by B16F10 cells than PNC, irrespective
of the corona. This difference highlights other potential role of albumin coating, such as particle
size reduction during the nanocrystal formation. In general, smaller sizes are preferred for the
uptake by non-phagocytic cells [35, 36], and larger particles are more readily taken up by
macrophages [37]. The particle size reduction is a unique feature of albumin coating and may be
further optimized.

Figure 33. Effect of serum proteins in NC-cell interactions. (a) Intracellular PTX content in
J774A.1 cells treated with PNC or Cim-F-alb in medium containing 50% mouse serum or serumfree medium for 0.5 h (n = 3). *p < 0.05; ****p < 0.0001 by two-way ANOVA with post-hoc
Sidak’s multiple comparisons test. (b) Intracellular PTX content in J774A.1 cells treated with
NCs ± 15 min corona (corona formed for 15 min) for 30 min in serum-free DMEM medium (n =
6) and B16F10 cells treated with NCs ± 15 min-corona for 3 h in serum-free RPMI-1640
medium (n = 3). *p < 0.05; **p < 0.01; ****p < 0.0001 by two-way ANOVA with post-hoc
Sidak’s multiple comparisons test.
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3.4

Biodistribution of Abxtal vs. Abraxane after multiple doses
Given that Cim-F-alb resists protein adsorption and achieves relatively favorable cellular

interactions, the BD profile of Cim-F-alb and Abraxane was studied at the pre-determined
maximum tolerated dose (30 mg/kg q3d × 5) to investigate accumulation over multiple doses
(Figure 34). None of the surviving animals lost body weight during the treatment (Supplementary
Figure 22).
Cim-F-alb showed significantly higher levels of paclitaxel in tumor, liver, and spleen than
Abraxane, similar to the observations following a single dose (Figure 29). Upon close comparison,
the results from single and multiple dosing revealed additional differences between Cim-F-alb and
Abraxane. When paclitaxel accumulation in tumor was compared between Cim-F-alb and
Abraxane, the difference was more prominent with multiple dosing: the differences at 24 h postinjection were 5.0 and 1.7 μg/g for multiple and single dosing, respectively. It was not the case for
the paclitaxel levels in the liver and spleen at 24 h post-injection. The differences in the liver
paclitaxel levels at 24 h post-injection were comparable (7.1 and 9.1 μg/g for multiple and single
dosing, respectively). So were the differences in the spleen paclitaxel levels at 24 h post-injection
(1.3 and 1.7 μg/g for multiple and single dosing, respectively). This indicates that multiple dosing
incurs tumor accumulation of Cim-F-alb to a greater extent than Abraxane, but not in other highly
perfused organs such as the liver, spleen, lung, kidney and heart. With a single surviving mouse,
comparison between PNC and the other treatments was not feasible, but its tumor level was no
higher than those of Cim-F-alb and Abraxane. The tumor growth rate, animal survival, and tumor
deposition collectively support that PNC was inferior to Cim-F- alb, as expected from the cellbased studies. Thus, PNC was not included in subsequent studies.
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Figure 34. Biodistribution of Abraxane, Cim-F-alb, and PNC at PTX 30 mg/kg q3d × 5 (at 24 h
post last injection). Abraxane (blue; n = 3), Cim-F-alb (red; n = 6), or PNC (green; n = 1). PTX
content in each tissue was determined by LC-MS. *p < 0.05 by two tailed t-test with post-hoc
Mann–Whitney test between Abraxane and Cim-F-alb.
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3.5

Anticancer efficacy of Abxtal vs. Abraxane at maximum tolerated dose
To evaluate if the cumulative Cim-F-alb exerts long-lasting suppression of tumor growth

after cessation of the treatment, the same dosing schedule was repeated, monitoring them till the
endpoint (Figure 35). Animals with no drug treatment (PBS group) reached the endpoint with a
median survival time of 11 d, reflecting the aggressiveness of the B16F10 tumors [38]. Abraxane
extended the median survival time to 15 d (p < 0.05 vs PBS group by log-rank test). Cim-F-albtreated animals showed the longest median survival time (21 d, p < 0.001 vs PBS group). The
specific tumor growth rates showed a similar trend, where Cim-F-alb achieved a significant delay
in tumor growth (p < 0.01 vs PBS; Tukey’s multiple comparisons test).
Abraxane appeared to have attenuated tumor growth during the treatment period, but tumors
grew soon after the final dose, rendering no significant difference from PBS in the tumor growth
rate. This result supports that Cim-F-alb had the anticancer efficacy that lasted longer than
Abraxane, likely due to the greater accumulation in tumor. Of note, the tumor concentrations of
paclitaxel at 24 h post-injection of the last dose (10.1 μg/g (11.8 × 10−6 M) for Cim- F-alb and 5.3
μg/g (6.2 × 10−6 M) for Abraxane) (Figure 34) were far higher than the in vitro IC50 value of
paclitaxel (94.3 to 926.7 × 10−9 M) in B16F10 cells, but tumors continued to grow and all animals
succumbed to death. This gap may result from distinct reasons for each treatment. For Abraxane,
the drug concentration may not have been maintained sufficiently long in tumors. Cim-F-alb may
have advantage over Abraxane in this regard due to the size, but its dissolution takes time. In
addition, as nanoparticles Cim-F-alb may not efficiently penetrate tumors [39]. This limitation
may in part explain why the differential tumor concentrations of paclitaxel did not translate to
statistically significant difference between Abraxane and Cim-F-alb in both median survival time
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and tumor growth rate. Further efforts need to be made to reduce the NC size so that its dissolution
and/or tumor penetration may be enhanced.

Figure 35. Anticancer activity of Abraxane and Cim-F-alb at PTX 30 mg/kg q3d × 5. PBS
(black; n = 7), Abraxane (blue; n = 5), or Cim-F-alb (red; n = 7). (a) Dosing schedule. (b)
Changes of individual B16F10 tumor volume. Arrows indicate the times of treatment. (c)
Kaplan–Meier survival curve. *p < 0.05; ***p < 0.001 versus PBS by log-rank test. (d) Specific
growth rate of B16F10 tumor. ΔlogV/Δt (V: tumor volumes; t: time in days). **p < 0.01 by
Dunn’s multiple comparisons test.
3.6

Conclusion
Cim-F-alb demonstrated that a stably circulating nanoparticle form of paclitaxel outperforms

the clinical gold standard Abraxane at the equivalent dose, with a minimal involvement of nondrug excipients. Outperformance at the equivalent dose is quite promising given that many new
nanoformulations demonstrate superior therapeutic outcomes to commercial benchmarks at
respective maximum tolerated doses, which are higher than those of commercial products [10, 40].
The low albumin content is also noteworthy. Though effectively controlled by donor screening
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and product manufacturing processes [41], albumin carries a remote risk of viral disease
transmission. With the reduced albumin content (12 wt% in Cim-F-alb vs 90 wt% in Abraxane),
Cim-F-alb has a lower risk for disease transmission, if any, than Abraxane.

3.7

Experimental

3.7.1 Materials
Paclitaxel was a gift of Samyang Biopharm (Seoul, Korea). Pluronic F127 (F127) was a
gift from BASF (New York, NY, USA). Abraxane was obtained from Celgene Corporation
(Summit,

NJ, USA). Human serum

albumin

(≥96% agarose

gel

electrophoresis),

hexadecyltrimethylammonium bromide (CTAB), and tert-butyl methyl ether (TBME) were
purchased from Sigma-Aldrich (St. Louis, MO, USA). C57BL/6 mouse serum was purchased from
Innovative Research (Novi, MI, USA). All other reagents were purchased from Fisher Scientific
(Waltham, MA, USA).
3.7.2 Pharmacokinetics and Biodistribution
All animal procedures were approved by Purdue Animal Care and Use Committee, in
conformity with the NIH guidelines for the care and use of laboratory animals. Male C57BL/6
mice (Envigo, Indianapolis, IN, USA; 6–8 weeks) were inoculated with B16F10 melanoma cells
(106 cells per animal) via subcutaneous injection in the upper flank of the right hind leg. When the
average tumor size reached 100 mm3 (9–10 d post-inoculation), mice received a single dose of
Abraxane or Cim-F-alb equivalent to paclitaxel 30 mg/kg by tail vein injection.
At pre-determined time points (0.5, 1, 3, 6, 12, and 24 h post-injection), three mice were
randomly selected and sacrificed for blood sampling and collection of major organs. The mice
were anesthetized with isoflurane, and blood was collected in heparin coated tubes by cardiac
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puncture. Plasma was collected by centrifugation at 1000 rcf for 5 min and kept frozen at −80 °C.
Major organs (heart, lung, liver, spleen, and kidney) were also harvested and stored at −80 °C until
analysis. Tumor and major organs were weighed and homogenized in PBS (0.1 g tissue per mL)
with an Omni Tissue Master 125 homogenizer (Kennesaw, GA, USA). For 100 μL of each tissue
homogenate and plasma, 40 ng of docetaxel was added as an internal standard and briefly mixed
with 1 mL of TBME by vortex mixing. After centrifugation at 3724 rcf for 10 min, 900 μL of
TBME phase was separated, evaporated, and reconstituted in 100 μL of a 1:1 mixture of 0.1% FA
ACN and 0.1% FA in water. An individual standard curve was prepared by spiking paclitaxel in
respective matrices (respective tissue homogenates or plasma) to yield the final concentrations of
10, 50, 100, 500, 1,000, 10,000, and 100,000 ng/mL and processed in the same way as the samples.
Paclitaxel quantification was performed with a 6550 iFunnel Q-TOF mass spectrometer
(Agilent Technologies, Santa Clara, CA, USA). Three microliter of sample was injected to a
Zorbax Extend C18 column (2.1 mm × 50 mm, particle size 1.8 μm) kept at 35 °C (Agilent
Technologies, Santa Clara, CA, USA). Mobile phase A was 0.1% FA in water, and mobile phase
B was methanol. It was run isocratically at 40% A/60%B with a flow rate of 0.4 mL/min. The
column was held at 90% B for 5 min between injections. Mass spectral data were obtained in
positive ion mode with a Dual Agilent Jet Stream, where drying gas temperature was 200 °C, and
sheath gas temperature was 350 °C with a flow rate of 11 L/min. Scan spectra were acquired over
the m/z range of 700–1000. As parent ions, [PTX+Na]+ and [DTX+Na]+ were monitored at the
m/z ratios of 876.3 and 830.3, respectively. Peak ratios of paclitaxel to docetaxel were plotted
against nominal concentration of paclitaxel to generate a calibration curve from each tissue.
The plasma paclitaxel concentration-time profiles were obtained by pooling the data from
multiple mice (a single point per mouse, three mice per sampling time). To estimate the PK
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parameters, noncompartmental analyses were performed using the sparse data option of
WinNonlin (version 7.0, Certara, NJ, USA), allowing computation of the standard errors
associated with estimated parameters.
3.7.3 Anti-cancer activity
B16F10 melanoma-bearing mice were prepared in the same manner as above. When the
average tumor size reached 100 mm3, mice received a total of five times of Abraxane (n = 6), CimF-alb (n = 6), or PNC (n = 6) (equivalent to 30 mg/kg paclitaxel) every 3 d via tail vein injection.
One day after the last dose (13 d after the 1st treatment), surviving mice were sacrificed, and tumor
and major organs were excised and stored at -80 °C until analysis. Another set of animals were
treated with PBS (n = 7), Abraxane (n = 5), or Cim-F-alb (n = 7) (equivalent to 30 mg/kg paclitaxel)
in the same dosing schedule except that they were monitored until the endpoint was reached.
During the survival period, tumor volume and body weight were monitored every day. The
length (L) and width (W) of each tumor were measured with a digital caliper, and the volume (V)
was calculated per the modified ellipsoid formula: V = (L × W2)/2 [42]. Specific growth rate of a
tumor was calculated as ΔlogV/Δt (V: volume in mm3, t: time in days) [43]. Weight loss in excess
of 20% body weight, or tumors reaching >10% body weight were considered the endpoint.
3.7.4 Serum protein corona analysis by LC-MS/MS
Cim-F-alb, PNC, and Cim-C-alb equivalent to paclitaxel 300 μg/mL were incubated in
undiluted mouse serum for 15 min or 3 h at 37 °C with rotation. The nanocrystals were
centrifuged at 135,700 rcf for 15 min at 4°C and washed with PBS two times. The nanocrystal
pellet (which contained protein corona) was treated with 10 μL of 10 × 10−3 M dithiothreitol
(DTT)/8m urea solution for 1 h at 37 °C to denature proteins and reduce disulfide bonds between
cysteines. Cysteines were then alkylated with a 2% solution of iodoacetamide in acetonitrile
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(ACN) at 37 °C for 1 h. Samples were dried by vacuum centrifugation and treated with LysC/trypsin (Promega, Madison, WI, USA). Digestion was performed using the Barocycler 2320
(Pressure Biosciences, Inc., Easton, MA, USA) for 1 h at 50 °C (120 cycles of 20 kpsi for 50 s
and atmospheric pressure for 10 s). Peptides were purified by MicroSpin C18 columns (Nest
Group, Inc., Southborough, MA, USA). Resulting pellets were resuspended in a 3% ACN/0.1%
formic acid (FA) solution. The samples were analyzed using the Dionex UltiMate 3000 RSLC
Nano System coupled to the Q Exactive HF Hybrid Quadruple-Orbitrap MS (Thermo Scientific,
Waltham, MA, USA). The peptides were loaded onto a trap column (20 μm × 350 mm) and
washed with a 98% purified water/2% ACN/0.01% FA at a flow rate of 5 μL min−1. The trap
column was then switched in-line with the analytical column after 5 min. Peptides were
separated by a reverse phase Acclaim PepMap RSLC C18 (75 μm × 150 mm) analytical column
at a flow rate of 300 nL min−1. Mobile phase A was 0.01% FA in water, and mobile phase B
was 0.01% FA in 80% ACN. The linear gradient started at 5% B and reached 30% B in 80 min,
45% B in 91 min, and 100% B in 93 min. The column was held at 100% B for the next 5 min
before being brought back to 5% B and held for 20 min. Samples were injected into the QE HF
through the Nanospray Flex Ion Source fitted with an emission tip from Thermo Scientific. Data
acquisition was performed focusing on the top 20 precursors at 120,000 resolution with an
injection time of 100 ms. Database searches of the UniProt_mouse proteins were performed
using Mascot Daemon v.2.5.1 (Matrix Science, Boston, MA, USA) with peptide mass tolerance
of 0.05 Da and fragment mass tolerance of 0.2 Da. The false discovery rate was adjusted to 1%.
Among the identified proteins, those with spectral counts fewer than 50 were excluded. The
relative abundance of each protein was estimated using the percentage molecular weight
normalized spectral count (MWNSC) by the following Equation:[44, 45]
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where SC is the spectral count of protein k and Mw is the molecular weight of the protein k (in
kDa).
3.7.5 Biolayer interferometry
The binding kinetics of NCs to mouse serum proteins were evaluated by biolayer
interferometry using an Octet Red384 system (Pall ForteBio, Fremont, CA, USA). The assays
were performed in a 96-well plate with 200 μL of ligands (mouse serum proteins) and analytes
(NC suspension) in each well. Mouse serum (50 μg/mL) was loaded on an amine reactive second
generation (AR2G) biosensor via EDC/NHS coupling. Different concentrations of PNC, Cim-Falb, and Cim-C (paclitaxel equivalent 3.125 to 200 μg/mL) in 10 × 10−3 M phosphate buffer (pH
7.4) were allowed to associate with the biosensor for 300 s, followed by dissociation for 600 s.
Nonspecific binding of nanocrystals to the sensor was subtracted from the signal. The binding data
was fitted to a global fit 2:1 heterogeneous ligand model using the Octet Data Analysis software
to determine the KD, kon, kdis, Χ2, and R2.
3.7.6 Cellular interaction
J774A.1 murine macrophage cells (ATCC, Manassas, VA, USA) were grown in DMEM
medium containing 10% fetal bovine serum (FBS) and penicillin (100 IU/mL) and streptomycin
(100 μg/mL). B16F10 mouse melanoma cells (ATCC, Manassas, VA, USA) were grown in RPMI1640 medium containing 10% FBS, penicillin (100 IU/mL), and streptomycin (100 μg/mL). Cells
were seeded in a 6-well plate at a density of 100,000 cells per well. Following overnight incubation,
the cell culture medium was replaced with the medium containing Cim-F-alb or PNC. Here, the
nanocrystals were suspended in serum-free medium or medium supplemented with 50% mouse
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serum (MS) to provide the final concentration of paclitaxel 30 μg/mL. Alternatively, the cells were
incubated with nanocrystals containing pre-formed corona. The nanocrystals were incubated in
undiluted MS for 15 min in 37 °C at the final paclitaxel concentration of 300 μg/mL and washed
with PBS two times by centrifugation at 135,700 rcf for 10 min at 4°C. The corona-coated
nanocrystals were provided to the cells as suspended in serum-free medium at the concentration
equivalent to 30 μg/mL paclitaxel. After incubation with each treatment for specified times, cells
were washed with PBS two times to remove unbound nanocrystals. The cells in each well were
collected and suspended in 500 μL of medium. Twenty microliters of the cell suspension was
analyzed with a flow cytometer (Accuri C6, BD Sciences, San Jose, CA, USA) to determine the
cell number. The rest of cell suspension was analyzed for the intracellular paclitaxel content. The
cell pellet was lysed with 3 cycles of freeze-thaw and probe sonication. Paclitaxel in the cell lysate
was extracted by TBME with carbamazepine as an internal standard and analyzed with HPLC
using an Agilent 1100 HPLC system (Palo Alto, CA, USA) equipped with Ascentis C18 column
(250 mm × 4.6 mm, particle size 5 μm). The mobile phase was 50% ACN and run at a flow rate
of 1 mL.
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APPLICATION OF ABXTAL FORMULATION TO
OTHER HYDROPHOBIC DRUGS

4.1

Introduction
As demonstrated in previous chapters, Abxtal offers greater therapeutic benefits than

existing formulations with a simple change in physical assembly of the components. Abxtal relies
on crystallization of poorly water-soluble small molecule drugs in water; therefore, Abxtal
technique is applicable to other hydrophobic drugs as well. Therefore, I demonstrated the broad
utility of Abxtal formulation with other anti-cancer drugs: docetaxel (DTX) and carfilzomib (CFZ).
Abxtal formulation of docetaxel entered drug-resistant NCI/ADR-RES ovarian cancer cells by
interactions with albumin-receptors, showing the potential utility in the treatment of multidrugresistant tumors. Abxtal formulation of carfilzomib protected the drug from enzymatic degradation,
leading to enhanced stability in biological media relative to the solvent- or cyclodextrin-solubilized
formulations.

4.2

Abxtal for docetaxel
Docetaxel is a taxane analog with low water-solubility (2.31 ± 0.05 μg/mL in PBS [1]), and

the commercial formulation (Taxotere® ) contains Tween 80, which is known to cause side effects,
including hypersensitivity reactions, peripheral neuropathy, and hemolytic activity [2]. Therefore,
an alternative formulation with minimal amount of excipients is needed.
In addition to the circulation stability achieved with nanocrystal form, we exploited the
benefit of NC form in the treatment of drug resistant cells compared to free drug form. NCI/ADRRES cells with high expression of P-glycoprotein (P-gp) were chosen as docetaxel-resistant cells
[3], and B16F10 cells were chosen as drug-sensitive cells. When cellular uptake of docetaxel was
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compared between free docetaxel and DTX-F-alb, different trend was found between B16F10 and
NCI/ADR-RES cells (Figure 36). In B16F10 cells, intracellular docetaxel levels were higher with
free docetaxel than DTX-F-alb in B16F10 cells because small molecules are more efficient in
entering the cells. This was consistent with the comparison between Abraxane and Cim-F-alb
(Figure 26), where molecularly-dispersed Abraxane entered B16F10 cells more efficiently than
nanoparticulate Cim-F-alb. On the other hand, greater docetaxel uptake was observed with DTXF-alb than free DTX in NCI/ADR-RES cells, likely due to nanocrystals bypassing P-gp efflux
pump [4].

Figure 36. DTX uptake by (a) B16F10, and (b) NCI/ADR-RES cells after (1 or) 3 h treatment
with free DTX and DTX-F-alb at a concentration equivalent to DTX 30 μg/mL. The total protein
content determined by micro-BCA assay was used for normalization. n = 2 independent and
identical experiments. *p < 0.05 and **p < 0.01 by unpaired t test with Welch’s correction.
Adapted with permission from [1]. Copyright 2018 American Chemical Society.
The involvement of surface-bound albumin in cellular transport of DTX-F-alb was studied.
Because the interstitial SPARC protein is known to mediate albumin transport [5], cellular uptake
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and cytotoxicity of free docetaxel and DTX-F-alb were compared after silencing SPARC with
siRNA targeting hSPARC (Figure 37). The hSPARC knockdown group (siSPARC) showed
significant decrease in uptake of DTX-F-alb when compared to the wild-type cells (WT) or
negative control siRNA treatment group (siNeg). On the other hand, cellular uptake of free
docetaxel did not change significantly with hSPARC knockdown. The trend remained consistent
in cell viability assessment, confirming the involvement of SPARC in cellular interaction of DTXF-alb. This result supports the contribution of the surface-bound albumin-SPARC interaction to
the treatment of multidrug-resistant cancer cells by Abxtal.

Figure 37. The effect of hSPARC silencing on (a) uptake (after 3 h treatment) and (b)
cytotoxicity (after 4 h treatment and 72 h follow-up incubation) of free DTX and DTX-F-alb at a
concentration equivalent to 30 μg/mL DTX. NCI/ADR-RES cells were incubated with siRNA
complex for 24 h, harvested, and re-plated for each treatment. n = 3 independent and identical
experiments. *p < 0.05, **p < 0.01, ***p < 0.001 by two-way ANOVA with Sidak’s multiple
comparisons test.
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4.3

Abxtal for carfilzomib
Carfilzomib, a second-generation proteasome inhibitor with efficient anticancer activity

against multiple myeloma, is a promising candidate compound for Abxtal formulation. Current
commercial formulation (Captisol® ) uses significant amount of sulfobutylether-β-cyclodextrin for
dissolution of poorly water soluble carfilzomib (1 μg/mL in pH 5 and 10 μg/mL in pH 3), which
results in limited drug loading (2 wt%). Moreover, injectable formulation of free carfilzomib
suffers from in vivo instability due to the inactivation of peptide backbone, resulting in a short
systemic circulation half-life of 1 h in human (Figure 38) [6-8].

Figure 38. Major metabolic pathways of carfilzomib from metabolite profiling in rat plasma,
urine, and bile samples. Reprinted with permission from [8]. Copyright 2011 American Society
for Pharmacology and Experimental Therapeutics.
Because of short circulation half-life and unfavorable biodistribution, current formulations
of the proteasome inhibitors are unable to treat solid tumors. For example, bortezomib (BTZ), a
first-generation proteasome inhibitor, showed complete proteasome inhibition in subcutaneous
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BPLER tumor in mice via intratumoral injection, whereas intraperitoneal and intravenous routes
were ineffective, indicating systemically administered bortezomib cannot reach the solid tumor in
a sufficient amount [9] (Figure 39).

Figure 39. Proteasome inhibition activity in vivo of bortezomib (BTZ). Proteasome activity in
protein lysates from BPLER tumors 18 hr after intratumoral (IT), intraperitoneal (IP), or
intravenous (IV) treatment with bortezomib (BTZ). Reprinted with permission from [9].
Copyright 2016 Springer Nature.
Abxtal formulation may present carfilzomib with opportunities to treat solid tumors by
overcoming the enzymatic instability because only the outermost surface of particle is affected and
the surface stabilizer can further protect the surface [10, 11]. Also, Abxtal can address the major
drawbacks of carfilzomib’s injectable formulation, such as off-target effects including
neurotoxicity [12], by improving BD profile of carfilzomib.
Abxtal formulation of carfilzomib (CFZ-alb NC) produced rod shape nanocrystals (Figure
40) with a length of length of 352 ± 195 nm and a width of 58 ± 15 nm (n=135 with Image J).
Although slightly longer, the shape of nanocrystals was similar to Abxtal formulation of paclitaxel.
When measured with dynamic light scattering, the size and surface charge of CFZ-alb nanocrystals
were 271.5 nm ± 24 nm and -13.8 mV ± 3 mV, respectively (n = 10 independent batches).
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Figure 40. TEM images and size analysis. Length and width of Abxtal formulation of CFZ from
randomly selected TEM images were analyzed with ImageJ. Scale bars: 200 nm.
X-ray powder diffraction analysis revealed the crystalline nature of as-received carfilzomib
and CFZ-alb nanocrystals with various sharp peaks characteristic of crystalline solids (Figure 41).
CFZ-alb nanocrystals showed lower peak intensity than as-received carfilzomib, indicating the
presence of albumin on the surface of NC.

Figure 41. X-ray powder diffraction patterns of as-received CFZ and CFZ-alb NC.
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When serum stability was tested, CFZ-alb nanocrystals maintained a linear relationship of
light scattering with nanocrystal concentration in FBS over 24 h (Figure 42), confirming the
physical stability of nanocrystals in the presence of serum. Therefore, CFZ-alb nanocrystal is
expected to circulate in blood as nanoparticles at least for 24 h at the tested concentrations (7-70
µg/mL), which include the initial blood concentration of nanocrystals given at the dose of 3 mg/kg
carfilzomib (24-40 µg/mL with a typical blood volume of a mouse of 1.5–2.5 mL).

Figure 42. Derived count rate of CFZ-alb NC in PBS (left) and undiluted FBS (right) at 37 °C.
For samples in FBS, the values were obtained by subtracting the derived count rate of FBS from
those of particle suspensions in FBS at each time point. n = 3 independently and identically
performed experiment.
To investigate the correlation of SPARC expression with albumin-mediated cellular
interactions, cellular uptake of CFZ-alb nanocrystal was studied in three different cells: MCF7,
4T1, and HCC1937 cells, which represent low, medium, and high SPARC expression, respectively.
To visualize and quantitate cellular uptake of CFZ-alb nanocrystals, CFZ-alb nanocrystals were
fluorescently labeled by doping with a small quantity of rhodamine B. The amount of incorporated
rhodamine B in *CFZ-alb nanocrystals was 0.34 ± 0.11 wt% (n=3).
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When examined in confocal microscope images, free rhodamine B showed little signal in all
of three cell lines. In contrast, rhodamine B signal was observed in the cytoplasm after 2 h
treatment with *CFZ-alb nanocrystals in 4T1 and HCC 1937 cells, indicating internalization of the
NC. Nanocrystal uptake was not evident in MCF-7 cells (Figure 43). Flow cytometry showed that
*CFZ-alb nanocrystal uptake was greatest with HCC 1937 cells, followed by 4T1 cells and MCF7 cells (Figure 44). These results suggest that SPARC expression may have influence on the
cellular uptake of CFZ-alb nanocrystals.

Figure 43. Intracellular localization of rhodamine B doped *CFZ-alb NC after 2 hours
incubation. Blue = nuclei, and red = rhodamine B. Scale bar = 10 μm.
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Figure 44. Fluorescence intensity MCF-7, 4T1, and HCC1937 cells after incubation with *CFZalb (30 μg/mL CFZ eq.) or 0.1 μg/mL rhodamine B for 2 hr, measured by flow cytometry.
**p<0.01, .***p<0.005 by one-way ANOVA post-hoc Sidak’s multiple comparisons test.
The enzymatic stability test demonstrated that Abxtal formulation maintains the stability of
carfilzomib against liver homogenate and whole blood over 60 min (Figure 45), relatively better
than free carfilzomib and cyclodextrin-formulation of carfilzomib. With improved metabolic
stability, Abxtal may improve systemic delivery of carfilzomib for therapy of solid tumors.

Figure 45. Metabolic stability of CFZ formulations in liver homogenate and whole blood sample
over 60 min. Closed circle: CFZ-F-alb, open circle: cyclodextrin-solubilized CFZ formulation,
and closed triangle: solvent-solubilized CFZ formulation. With courtesy of Ji Eun Park at Seoul
National University.
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4.4

Conclusion
The broad utility of Abxtal formulation as an enabling formulation for hydrophobic small

molecule drugs was demonstrated with docetaxel and carfilzomib. The interaction of docetaxel
Abxtal with albumin-receptor contributed to the treatment of drug-resistant cells. Also, the benefit
of Abxtal formulation in overcoming enzymatic instability of drug was demonstrated. The Abxtal
formulation of carfilzomib showed enhanced stability in biological media relative to the solventor cyclodextrin-solubilized formulations.

4.5

Experimental

4.5.1 Materials
Pluronic F127 (F127) was a gift from BASF (New York, NY, USA). Human serum
albumin (≥96% agarose gel electrophoresis) was purchased from Sigma-Aldrich (St. Louis, MO,
USA). All other reagents were purchased from Fisher Scientific (Waltham, MA, USA).
4.5.2 Production of Abxtal of carfilzomib
CFZ-alb nanocrystal was produced by crystallizing carfilzomib in the presence of F127
and coating the resulting nanocrystals with albumin as reported previously. Briefly, 6 mg of
carfilzomib and 48 mg of F127 were dissolved in a mixture of 3 mL of chloroform and 1 mL of
methanol and dried in a round bottom flask by rotary evaporation at 40˚C for 10 min. The dry
drug-polymer film was hydrated with 6 mL of water with bath sonication for 10 s, and the
suspension was probe-sonicated for 5 min with an amplitude of 40% and a 4:1 duty cycle every 5
s in ice bath. Subsequently, the suspension was incubated with 48 mg of human serum albumin
for 24 h at room temperature on a rotating shaker. Excess surfactant and unadsorbed albumin were
removed by centrifugation at 135,700 rcf for 15 min at 4˚C. Optionally, CFZ-alb nanocrystal was
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fluorescently labeled by adding rhodamine B as 0.1 mg/mL aqueous solution during the film
hydration step. The rhodamine B-labeled CFZ-alb nanocrystal was called *CFZ-alb nanocrystal.
To quantify the incorporated rhodamine B, fluorescence intensity (λex/λem = 540 nm/625 nm) of a
known amount of NC dissolved in acetonitrile (ACN) was measured with a SpectraMax M3
microplate reader (Molecular Devices, CA, USA). Most in vitro studies were performed with
freshly prepared CFZ-alb. For in vivo studies, CFZ-alb nanocrystal was lyophilized with trehalose
as a cryoprotectant (CFZ-alb nanocrystal:trehalose = 1:5).
4.5.3 Characterizations
4.5.3.1 Size and surface charge
The size and surface charge of nanocrystals were measured with a Zetasizer Nano-ZS90
(Malvern Instruments, Westborough, MA, USA). NCs were diluted in phosphate buffer (1 mM,
pH 7.4)
4.5.3.2 Morphology
The morphology of nanocrystals was examined with a Phillips CM-100 transmission
electron microscopy (FEI Company, Hillsboro, OR, USA). Samples were mounted on a 400-mesh
Cu grid with Formvar/carbon supporting film, followed by negatively staining with 1% uranyl
acetate. Images were captured with a SIA L3-C2 megapixel CCD camera (Scientific Instruments
and Application, Duluth, GA, USA). The size of NC was analyzed from TEM images with ImageJ
(National Institutes of Health, Bethesda, MD, USA).
4.5.3.3 Carfilzomib content
The carfilzomib content in nanocrystal was determined by HPLC. Nanocrystal with a premeasured mass was dissolved in a 50:50 mixture of ACN and water and filtered with 0.45 μm

88

syringe filter. HPLC was performed with an Agilent 1100 HPLC system (Agilent, Palo Alto, CA,
USA), equipped with Ascentis C18 column (25 cm x 4.6 mm, particle size: 5 μm). The column
was initially equilibrated with 40% of ACN, followed by a linear gradient of ACN from 40% to
80% over 10 min and from 80% to 40% over the next 10 min at a flow rate of 0.7 mL/min.
Carfilzomib was detected with a UV detector at a wavelength of 210 nm.
4.5.3.4 Albumin content
The albumin content in nanocrystals was quantified with SDS-PAGE. Nanocrystals with a
known mass or albumin standard solutions were mixed with 4× Laemmli sample buffer and heated
at 95˚C for 5 min to separate albumin from NC. The samples were resolved in a 12%
polyacrylamide gel and stained with QC Colloidal Coomassie Stain (Bio-Rad, Hercules, CA,
USA). The stained gel was imaged with Azure C300 (Azure Biosystems, Dublin, CA, USA), and
albumin bands were quantified by densitometry function of the AzureSpot Analysis Software
(Azure Biosystems, Dublin, CA, USA). The albumin content was determined by comparing the
band intensity of NC and albumin standards.
4.5.3.5 X-ray powder diffraction
CFZ drug and CFZ-alb NC were analyzed with a Rigaku SmartLab diffractometer (Rigaku
Americas, The Woodlands, Texas, USA) equipped with a Cu-Kα radiation source. The powder
samples were placed on glass holder, and diffraction patterns were obtained from 5 to 40˚ 2θ at a
scan speed of 4˚ per minute and a step size of 0.02˚. The voltage and current used were 40 kV and
44 mA, respectively.
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4.5.4 Serum stability of Abxtal formulation of carfilzomib
To predict the physical stability of CFZ-alb, we resorted to a linear correlation between the
number of particles and light scattering intensity 1-2. The derived count rate (i.e., absolute light
scattering) of NC suspension ranging from 7.2 μg/mL to 72 μg/mL was measured in PBS or
undiluted fetal bovine serum (FBS) at 37ear correlation between the number of particles
aInstruments, Westborough, MA, USA). The derived count rate of FBS was subtracted from each
measurement made in FBS. In a separate experiment, the dissolution of CFZ-alb nanocrystal in
FBS was monitored by measuring the count rate continuously over 20 min at the final
concentration equivalent to 7.2 or 30 μg/mL of carfilzomib. Measurements were made twice every
two seconds at the measurement position of 4.65 nm and with an attenuator setting of 10.
4.5.5 Cellular uptake of Abxtal formulation of carfilzomib
4T1 mouse breast cancer cells, MCF-7 human breast cancer cells, and HCC1937 human
breast cancer cells (ATCC, Manassas, VA, USA) were grown in RPMI-1640 medium
supplemented with 10% FBS, penicillin (100 IU/mL) and streptomycin (100 μg/mL). Cells were
seeded in a 35 mm glass bottom dish (MatTak, Ashland, MA, USA) at a density of 50,000 cells
per dish. After 24 h, the medium was replaced with fresh medium, and the cells were incubated
with rhodamine B labeled CFZ-alb nanocrystal (*CFZ-alb NC) equivalent to 30 μg/mL
carfilzomib or free rhodamine B solution at a comparable level for 2 h in complete medium. After
two times of washing with PBS, the cells were fixed with 4% paraformaldehyde in PBS for 10
min. Following nucleus staining with Hoechst 33342 (2 μg/mL), cells were imaged with a Nikon
A1R confocal microscope (Nikon America Inc., Melville, NY, USA). Hoechst 33342 and *CFZalb nanocrystal or free rhodamine B were detected with λex/λem of 407 nm/425–475 nm and 561
nm/570–620 nm, respectively. For quantitative comparison, the cells were prepared as described
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above and analyzed with Accuri C6 flow cytometer (BD Biosciences, San Jose, CA, USA). At
least 10,000 gated events were acquired, and FL-2 channel (λex/λem 488 nm/585 nm) was monitored
to determine the cellular level of rhodamine B.
4.5.6 siRNA-mediated knockdown of hPSARC
NCI/ADR-RES cells were plated in 6-well plates (3 × 105 cells per well) and cultured
overnight. Cells were then transfected with siRNAs targeting hSPARC or control scrambled
sequences (25 pmol/well, OriGene, Rockville, MD, USA) using Lipofectamine RNAiMAX
(Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instruction. After
24 h incubation with siRNAs, cells were harvested and re-plated for another 24 and 48 h incubation
in fresh medium.
4.5.7 Cellular uptake and cytotoxicity of DTX-F-alb
NCI/ADR-RES cells were treated with with DTX-F-alb or free docetaxel for 3h at at a
concentration equivalent to 30 or 40 μg/mL (37.1 or 49.5 μM) docetaxel. After removing the
treatments, cells were collected and lysed by three cycles of freeze-thaw, followed by probe
sonication. The total protein content in cell lysate was analyzed using the micro-BCA protein assay
and used for normalization. After adding carbamazepine as an internal standard, each cell lysate
was subjected to liquid−liquid extraction tert-butyl methyl ether. The organic phase was separated
by centrifugation at 3,724 rcf for 10 min, dried under vacuum, reconstituted with acetonitrile, and
analyzed with HPLC.
4.5.8 Cytotoxicity of DTX-F-alb
NCI/ADR-RES cells were treated with DTX-F-alb or free docetaxel for 4 h, and the medium
was replaced with drug-free medium for 48 h. Then, the cell viability was measured by the MTT

91

assay [13]. The absorbance at 562 nm was measured using a SpectraMax M3 microplate reader
(Molecular Devices, CA, USA).
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COMBINATION OF CHEMOTHERAPY WITH
IMMUNOTHERAPY

5.1

Introduction
Although optimally-designed nanoparticle systems can enhance cancer-specific delivery of

chemotherapeutics and prolong survival in the preclinical studies, tumors ultimately relapse after
the cessation of treatments, which indicates inherent limitations of chemotherapy. On the other
hand, immunotherapy, such as immune checkpoint-blockade (ICB), promotes cytotoxic T-cell
activities and demonstrated impressive therapeutic responses [1]. However, the critical
shortcoming of immune checkpoint blockade therapy is that the benefit extends to only 20-40% of
patients because many tumors lack lymphocyte infiltration [2]. I hypothesize that nanoparticles
will improve immune checkpoint blockade by multiple mechanisms: by (i) increasing tumor
delivery of chemotherapeutics that induce immunogenic cell death (ICD); (ii) altering uptake
mechanism and consequent changes in the intracellular stress; (iii) creating personalized neoantigens in situ, (iv) binding and retention of neo-antigens on the nanoparticle surface for efficient
delivery to antigen presenting cells (APCs); and (v) co-delivery of immune adjuvants. The
potential of nanoparticles to promote immunogenicity of tumors has not been investigated
systematically because many studies employed xenograft tumor models in immunodeficient mice
[3], whose adaptive immunity is impaired.

Therefore, I intend to explore the utility of

nanoparticles in synergizing immune checkpoint blockade therapy.

5.2

Potential roles of chemotherapy in immune checkpoint blockade therapy
Immune checkpoint blockade (ICB) therapy aims to promote cytotoxic T-cell activities

against cancer by blocking cellular checkpoint receptors, such as cytotoxic T lymphocyte antigen
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4 (CTLA4) and programmed cell death protein (PD-1) or its ligand (PD-L1) [1]. However, this
modality of therapy predicates on the presence of pre-filtrated T cells in the tumor, so many tumors
that lack pre-existing immune response are refractory to immune checkpoint blockade treatments
[2]. Therefore, a complementary treatment to increase immunogenicity of tumor is needed to
expand the benefits of immune checkpoint blockade therapy.
Several chemotherapeutics are identified as inducers of immunogenic cell death, an immunestimulatory form of cell death that activates innate immune responses and elicits tumor-specific
immune responses [4, 5]. Immunogenically dying cells include damage-associated molecular
patterns (DAMPs). The pre-apoptotic exposure of the endoplasmic reticulum chaperone
calreticulin (CRT) protein to the surface of plasma membrane serves as an eat-me signal and
promotes the engulfment by dendritic cells [6]. Active secretion of ATP during the blebbing phase
of apoptosis stimulates the recruitment and maturation of macrophages and induces proliferation
of NK cells [7]. The post-apoptotic release of the nuclear chromatin binding protein, high mobility
group box1 (HMGB1), mediates toll-like receptor 4 (TLR4) and activation of B and T cells [8].
These signals promote the uptake of apoptotic bodies by antigen presenting cells and subsequent
induction of adaptive immune responses to the antigen [4] (Figure 46).
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Figure 46. Molecular and cellular mechanisms of immunogenic cell death. Cancer cells emit a
spatiotemporally ordered combination of damage-associated molecular patterns (DAMPs).
DAMPs promote the recruitment of antigen-presenting cells (APCs) and stimulate their ability to
cross-present dead cell-associated antigens to CD8 cytotoxic T lymphocytes (CTLs) while
secreting interleukin (IL)-1b. In addition, some CTLs acquire a memory phenotype, underlying
the establishment of long-term immunological protection. Reprinted with permission from [4].
Copyright 2014 Tayor & Francis.
Immunogenic cell death-inducing chemotherapy is expected to synergize with immune
checkpoint blockade therapy. At the same time, cytotoxic chemotherapeutics may pose a risk of
immunosuppression. To my knowledge, there is no consensus on how the dose/dosing schedule
play a role in immunogenic cell death. Wu et al. proposed medium-dose intermittent chemotherapy
(MEDIC) for effective immunogenic chemotherapy [9] (Figure 47). The authors suggest that an
optimal duration of drug-free break is required to allow endogenous tumor-reactive immune cells
to give time to expand. Over 9-days of drug free break could lead to immune suppression and drug
resistance, while too short drug free period will kill anti-tumor immune cells. In terms of the dose,
excessive dose kills immune cells, and residual chemo-resistant tumor cells will grow back. Low
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dose may spare immune cells, but remaining tumor cells can escape or subvert immunity. If this
principle holds for other immunogenic cell death inducing chemotherapeutics, one may expect that
chemotherapy with a medium dose and intermittent interval will provide optimal outcomes in
combination therapy with immune checkpoint blockade.

Figure 47. Implications of chemo-immunotherapy schedules. (A) A single injection of a cancer
chemotherapeutic drug may induce multiple events, including changes in the number of tumor
tolerant immune cells (a, black line), chemotherapy treatment-induced drug cytotoxicity (b,
orange cone), followed by lymphopenia (c, blue line) and immune stimulatory signals (d, pink
dashed line). The immune stimulatory signals activate anti-tumor immune responses (e, red line),
followed by increased immune suppression and drug resistance (f, green line). (B) An optimal
drug-free break allows for an overall increase in anti-tumor immune response. (C) A drug-free
break that is too long may enable the development of immune suppression and the emergence of
drug resistance. (D) A drug-free break that is too short ablates anti-tumor immune responses
prematurely. Reprinted with permission from [9]. Copyright 2018 Elsevier.
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5.3

Potential utility of nanoparticles in immune checkpoint blockade therapy
In addition to delivery of immunogenic cell death inducers, nanoparticles can provide

additional benefits to immunotherapy. The vehicle can bind and collect neo-antigens produced at
the tumor site by remaining in situ. A recent study showed that PLGA nanoparticles capture tumor
neo-antigens released from radiotherapy and efficiently deliver them to antigen presenting cells
[10] (Figure 48).

Figure 48. Schematic depiction of utilizing nanoparticles to improve cancer immunotherapy.
After radiotherapy, NPs bind to tumor antigens and improve their presentation to dendritic cells.
Reprinted with permission from [10]. Copyright 2017 Springer Nature.
Additional benefit of nanoparticle systems in immunotherapy is the potential to co-deliver
immunoadjuvants. For example, liposomes can co-deliver a TLR 9 agonist, CpG peptide, to induce
cytotoxic T-cell recruitment and reduce the immunosuppressive mediators [11].

98

Another potential mechanism for nanoparticles to be a more potent immunogenic cell death
inducer than the free drug counterpart is the change in uptake pathway. One study reported that
PEG-PLGA nanoparticles encapsulating oxaliplatin induced greater DAMP signals than free
oxaliplatin. The authors attributed the result to differential uptake pathways, although the detailed
mechanism is unclear [12] (Figure 49). Therefore, it is reasonable to postulate different uptake
mechanism can correlate with trafficking and damage to different sub-cellular organelles.

Figure 49. Exposure of DAMPs by human pancreatic cancer cells after treatment with different
drug formulations. NP: mPEG-PLGA nanoparticles. (Left) Amount of released ATP and (Right)
Percentage of CRT-positive cells. N.S., no significance. **, p < 0.01. ***, p < 0.001. Adapted
with permission from [12]. Copyright 2016 Elsevier.
5.4

Evaluation of immunogenic cell death
The gold-standard method to evaluate the ability to immunogenic cell death is vaccination

approach [13]. Cancer cells are exposed to the treatment of interest in vitro and inoculated into one
flak of immunocompetent mice. After 1 week, mice are re-challenged with living cancer cells in
the opposite flank. The rejection of the challenged tumor indicates that the treatment is a bona fide
immunogenic cell death inducer [4] (Figure 50).
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Figure 50. Vaccination assays. Murine cancer cells of choice are exposed in vitro to a putative
inducer of ICD (6–24 hr), then injected s.c. into one flank (vaccination site) of
immunocompetent syngeneic mice. One week later, mice are challenged with living cancer cells
of the same type, which are inoculated s.c. into the contralateral flank (challenge site). Tumor
incidence and growth are routinely monitored at both injection sites over a 1-2 months period.
Adapted with permission from [4] . Copyright 2014 Tayor & Francis.
Meanwhile, vaccination-based approach is not suitable for screening a large number of
compounds because of significant time and cost requirement, in addition to the limited number of
syngeneic tumor models [4]. Alternatively, DAMP signals (Section 5.1.1) may be detected in vitro
as surrogate markers for immunogenic cell death to screen the ability to induce immunogenic cell
death [14] (Figure 51).

Figure 51. Spatiotemporal pattern of the delivery of immunogenic signals from tumor cells that
undergo immunogenic cell death to dendritic cells, which in turn prime an anticancer T cell
response. Reprinted with permission from [14]. Copyright 2014 Tayor & Francis.
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5.5

Selection of tumor models
For the choice of tumor models, variable immunogenicity of tumors was considered. Only

a group of tumors is known to contain infiltrated T cells (“hot tumor”), and many tumors are
lacking pre-existing immune responses (“cold tumor”). Since immune checkpoint blockade
efficacy is predicated on the pre-existing T cells, many preclinical studies have been conducted
with hot tumors, such as CT26 colon cancer models [15]. However, there is an unmet need for
converting cold tumors, which are refractory to immune checkpoint blockade, to hot tumors.
Therefore, I chose B16F10 melanoma as poorly immunogenic tumor model (Figure 52).

Figure 52. Variable immunogenicity levels observed among murine solid tumor models in vivo.
IHC showing MHC class I molecule H2-Dd (BALB/c) or H2-Db (C57BL/6) expression in tumor
models. Adapted with permission from [15]. Copyright 2013 Lippincott Williams.
5.6

Selection of nanoparticle systems
For NP systems, Abxtal formulation and polymeric nanoparticles were considered as

robustly characterized systems. A novel nanoencapsulation strategy based on strong interfacial
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cohesion and supramolecular organization of iron-tannic acid complex, polymerized tannic acid
(pTA), was also considered. This method forms a capsule-type nanoparticles (“nanocores”) that
encapsulate a large amount of paclitaxel [16]. Tannic acid, the building block of pTA, is known to
be very reactive to polycyclic aromatic structures via multiple mechanisms including hydrogen
bonding and electrostatic interactions [17]. Although it is uncertain whether the chemical reactivity
of pTA is comparable to that of tannic acid, pTA nanocore is expected to serve as adhesive
platform and expects to show benefits in binding and transport of neo-antigens.

5.7

Immunogenic cell death induction with nanoparticle formulations of chemotherapy

5.7.1 Abxtal formulation
A group of chemotherapeutics, such as anthracyclines, oxaliplatin (OXA), and bortezomib
(BTZ), has been identified as immunogenic cell death inducers. To validate the evaluation method,
a group of drugs, including paclitaxel, carfilzomib, doxorubicin (DOX), and bortezomib, was
tested along with Abxtal formulation of paclitaxel and carfilzomib (Figure 53). Doxorubicin and
bortezomib were included as positive controls, but their primary DAMP signal response associated
with endoplasmic reticulum stress (calreticulin exposure) was not greater than other treatments.
Interestingly, carfilzomib was comparable to doxorubicin and bortezomib in ATP release and
HMGB1 release.
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Figure 53. DAMP signal measurements after treatment of B16F10 cells with PTX, CFZ, DOX,
BTZ, or Abxtal formulations of PTX and CFZ. The duration of treatment was either 3h (CRT) or
24 h (HMGB1, ATP, and Annexin V/PI). The treatment was equivalent to 10 μM of drug.
However, the interpretation of data is complicated by the treatment dose. The drug
concentration was chosen as 10 μM, to accommodate the comparison with Abxtal formulation,
whose solubility is in micromolar range, but the high dose might have caused excessive toxicity.
Relative cytoxicity of drug molecules in B16F10 cells was evaluated by the MTT assay, and the
dose used in the previous study was indeed 1000 times higher than IC50 values (e.g. typically in
range of 10 to 100 nM for paclitaxel, carfilzomib, doxorubicin, and bortezomib). Therefore, future
studies should be performed at equi-potent doses to avoid the misinterpretation from cytotoxicity
of drug tested.

103

It is likely that immunogenic cell death originates from the oxidative-endoplasmic
reticulum (ER) stress [18] (Figure 54). Therefore, prospective immunogenic cell death inducers
may be identified based on the mechanism of actions of drug candidates. For example,
carfilzomib inhibits proteasome activity leading to a build-up of intracellular proteins and
subsequent endoplasmic reticulum stress and thus can be pursued as a potential immunogenic
cell death inducer.

Figure 54. The activity of Type I immunogenic cell death (ICD) inducers. Type I ICD inducers
are modalities that induce cell death via non-ER associated targets and danger signaling via ER
stress. Adapted with permission from [18]. Copyright 2015 UPV/EHU Press.
5.7.2 Polymeric nanoparticle formulation
Since PLGA nanoparticle formulation can be compared at low dose, NP formulation of
carfilzomib was compared with free carfilzomib at 10 nM (Figure 55). The result is difficult to
interpret due to the absence of positive control, but no significant benefit from nanoparticle
formulation was observed.
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Figure 55. DAMP signal measurements after treatment of B16F10 cells with CFZ, or PLGA NP
formulation of CFZ (CFZ@PLGA NP). The duration of treatment was either 3h (CRT) or 24h
(ATP, and Annexin V/PI). The treatment was equivalent to 10 nM of drug.
5.7.3 Nanocore formulation
As a novel formulation, tannic acid-based nanocapsule, or pTA nanocore, was
hypothesized to be potentially immunogenic system because its potential bioactivity has not been
completely understood yet, but only known to have minimal toxicity in HeLa cells [16]. pTA
nanocore formulation (CFZ@pTA) was tested against free carfilzomib, but there was no notable
difference between the two in DAMP signal production (Figure 56). Interestingly, free pTA
showed comparable calreticulin exposure and ATP release when compared to other treatment
groups, but it remains to be confirmed with repeated experiments (n=1). There are two caveats in
interpretation of this result: the cellular uptake of pTA NP and drug release from pTA nanocore
have not been clearly investigated yet. The insignificant difference between carfilzomib and
CFZ@pTA in DAMP signals may be explained by burst release of carfilzomib from the pTA
core, excessive retention of drug in the pTA NP, or minimal cellular uptake of pTA NP, which
need to be clarified in the future studies.
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Figure 56. DAMP signal measurements after treatment of B16F10 cells with CFZ, or pTA
formulation of CFZ (CFZ@pTA). The duration of treatment was either 3h (CRT) or 24h (ATP,
HMGB1 and Annexin V/PI). The treatment was equivalent to 10 nM of drug.
Although not manifested in vitro level, pTA could potentially function as antigen transport
as a reactive layer because it is known to strongly interact with polycyclic aromatic structures via
multiple mechanisms including hydrogen bonding and electrostatic interactions [17]. Since neoantigen formation, transport to antigen presenting cells, and antigen-specific activation are
difficult to coordinate in vitro, in vivo study was planned.

5.8

Evaluation of immune response in vivo
C57BL/6 mice will be inoculated with B16F10 tumors in both hindlimbs, and one site

received the treatments (PBS, carfilzomib, free pTA, carfilzomib plus free pTA, or CFZ@pTA)
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intratumorally (Figure 57). The route of administration was important for proper comparative
evaluation because systemic administration is compounded by differential bioavailability and
biodistribution. Therefore, intratumoral injection was chosen to ensure consistent delivery of
drug/vehicle to the tumor.
The dose of drug was carefully selected. As mentioned in the earlier section, too low dose
will leave a group of cancer cells for recurrence, while too high dose may not spare immune
cells. Therefore, the IC50 concentration of carfilzomib was targeted for the initial experiment,
considering the volume of tumor (e.g. carfilzomib equivalent to 10 nM in 0.1 mL tumor).
On day 6 of post-treatment, tumors will be harvested and immunophenotyped for cytotoxic
T cells (CD8+), regulatory T cells (CD4+), and PD-L1 expressing cells. In addition, splenocytes
will be stimulated with irradiated B16F10 cell lysate (neo-antigen), and IFN-γ producing T-cells
will be measured by ELISPOT to evaluate antigen-specific T-cell activation.
With the current hypothesis that the reactive pTA surface will attract antigens efficiently
and retain for uptake by antigen presenting cells, free carfilzomib plus free pTA and CFZ@pTA
groups will improve immunogenicity better than free carfilzomib or free pTA group. Between
free mixture and carfilzomib encapsulated pTA NP, CFZ@pTA may have an advantage over
free carfilzomib if the drug release is attenuated. Free carfilzomib is subject to diffuse out of the
tumor tissue, whereas CFZ@pTA is likely to stay longer in the tumor tissue because of its size. If
the dose used in the study (carfilzomib 10 nM) is too low to induce sufficient cytotoxicity within
the tumor cells and subsequent antigen presentation, different doses need to be empirically
determined.
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.
Figure 57. The experimental scheme of in vivo evaluation of chemotherapeutic delivery by pTA
NP. C57BL/6 mice will be inoculated with B16F10 tumors in both hindlimbs, and one tumor
will be treated with PBS, CFZ, free pTA, CFZ plus free pTA, or CFZ@pTA intratumorally (e.g.
CFZ equivalent to 10 nM). The tumor growth will be monitored every day, and, on day 6 of
post-treatment, tumors and spleen will be collected. Tumors will be immunophenotyped (CD4+,
CD8+ and PD-L1+ populations), and spleen will be stimulated with irradiated B16F10 cell lysate
for evaluation of IFN-γ producing T cells.
5.9

Conclusion
The role of immunogenic cell death and nanoparticles in immunotherapy has not been fully

explored yet, partly due to common use of human tumor xenografts in immunodeficient mice.
However, the potential for successful clinical translation is very high because both nanoparticlebased chemotherapy and immunotherapy are currently available. In fact, combinations of
chemotherapies and immune checkpoint blockade agents are currently investigated in many
clinical trials [19] (Figure 58).
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Figure 58. List of ongoing clinical trials of checkpoint inhibitors plus nab-paclitaxel-based
chemotherapy in solid tumors. Reprinted with permission from [19]. Copyright 2016 Dove Press
Ltd.
Phase III clinical trial evaluating the therapeutic outcomes of combination of Abraxane
and atezolizumab (anti-PD-L1 antibody) is currently ongoing for treatment of metastatic triple
negative breast cancer [20]. Another Phase III clinical trial examined therapeutic benefits of
adding ipilimumab (anti-CTLA-4 antibody) to chemotherapy regimen (paclitaxel plus
carboplatin) in treatment of squamous non-small cell lung cancer [21].
Once the optimal nanoparticle system is determined, the synergistic effect in combination
with immunotherapy for durable response will be achieved, and the current benefits of
immunotherapy will be extended to patients previously refractory to the conventional immune
checkpoint blockade therapy.
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5.10 Experimental
5.10.1 DAMP signal evaluation
5.10.1.1 Calreticulin (CRT) protein exposure
B16F10 melanoma cells were seeded into 6-well plates at a density of 105 cells per well.
Next day, cells were treated with drug/nanoparticles in serum-containing medium for 3 h. The
cells were washed with PBS two times and fixed in 0.25% paraformaldehyde in PBS for 5 min at
room temperature. Fixed cells were stained incubated Alexa Fluor 488-conjugated rabbit anticalreticulin (CRT) antibody in 10% goat serum in PBS at 4˚C for 30 min at room temperature.
After washing with PBS once, cells were analyzed by flow cytometry, and the CRT positive cells
were detected by FL1 detector (533 nm) [12, 22-24].
5.10.1.2 HMGB1 protein and ATP release
B16F10 melanoma cells were seeded into 6-well plates at a density of 105 cells per well.
Next day, cells were treated with drug/nanoparticles in serum-containing medium for 24 h. After
treatment, the conditioned cell culture medium was analyzed for HMGB1 and ATP release. For
HMGB1 release, 20 μL of conditioned culture medium out of 1 mL was loaded in 12%
polyacrylamide gel and separated by SDS-PAGE, and HMGB1 protein was detected by Western
blotting using an anti-mouse HMGB1 antibody[12]. For ATP release, 10 μL of conditioned
culture medium out of 1 mL was analyzed by an ATP Determination Kit according to the
manufacturer’s specifications (Molecular Probes, Eugene, OR, USA) [12, 22].
5.10.2 Cell apoptosis evaluation
B16F10 melanoma cells were seeded into 6-well plates at a density of 105 cells per well.
Next day, cells were treated with drug/nanoparticles in serum-containing medium for 24 h. After
treatment, dead cells floating in the supernatant were collected, combined with the attached cells,
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and washed once by PBS. The apoptosis of cells was evaluated by FITC Annexin V/Dead Cell
Apoptosis Kit (Molecular Probes, Eugene, OR, USA). Briefly, the cells were suspended in 100
μL of 1X annexin-binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2, pH7.4) and
stained with 5 μL of Annexin V-FITC and 1 μL of propiodium iodide (PI) solution (100 μg/mL)
for 15 min at room temperature in dark. After incubation, 400 μL of 1X annexin-binding buffer
was added, and the stained cells were analyzed by flow cytometry. FITC was detected in FL1
detector (533 nm) and PI was detected in FL3 detector (670 nm). The cells were classified into
three populations: live (Annexin V and PI negative), early apoptosis (Annexin V positive and PI
negative), and late apoptosis/dead (Annexin V and PI positive).
5.10.3 Anti-tumor immunity evaluation
C57BL/6 mice (7 week) were subcutaneously inoculated with 106 B16F10 cells via
subcutaneous injection on both hindlimbs. When one of two tumors reached 100mm3, treatments
(paclitaxel, carfilzomib, free pTA, carfilzomib plus free pTA, and CFZ@pTA) were
administered to the tumor intratumorally. Fifty microliter was injected to 100 mm3 tumor to
achieve the final carfilzomib concentration of 10 nM (IC50 value obtained with B16F10 cells).
On day 6 of post-treatment, mice were sacrificed and both tumors and spleen were excised.
For immunotyping, tumors were filtered through 70 μm cell strainer, followed by another
filtration through 40 μm cell strainer to obtain single cell suspensions. The number of cells is
counted by hemocytometer, and 106 cells were aliquoted. The aliquoted tumor cells were
incubated with Fc block for 5 min and stained with anti-mouse CD4, CD8, and PD-L1 antibodies
for 30 min in ice. After washing, cells were fixed with 1% paraformaldehyde and analyzed by
FACS. Fluorescence-minus-one (FMO) control was used for appropriate compensation. For
evaluation of cytotoxic T lymphocytes’ activation, spleen was filtered through 70 μm cell
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strainer, followed by another filtration through 40 μm cell strainer to obtain single cell
suspension. Incubation of splenocytes with ammonium-chloride-potassium (ACK) buffer for 1
min removed red blood cells. Then, the cells were stimulated 100 μg/mL of 100 irradiated
B16F10 tumor lysate, and IFN-γ producing T cells were analyzed with ELISPOT Kit according
to manufacture’s instruction. The irradiated tumor lysate was prepared by exposing B16F10 cell
culture flasks to irradiation (2 Gy/min for 50 min; total 100 Gy), followed by 48 h culture in
serum-free medium. The protein content of lysate was determined by BCA assay.
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CONCLUSIONS

6.1

Summary of research
The study with albumin-coated nanocrystal (Abxtal) of paclitaxel described in Chapters 2

and 3 demonstrated that nanoparticles with high drug loading efficiency and long circulation
stability lead to superior anti-tumor efficacy in vivo compared to Abraxane, proving the original
hypothesis: the high drug loading and circulation stability are critical to improving therapeutic
outcome. Study of serum protein binding kinetics to Abxtal found that soft protein corona varied
with the surface chemistry of nanoparticles, and albumin coating provided protective effects
against opsonization in the initial deposition phase of Abxtal.
Abxtal formulations of docetaxel and carfilzomib in Chapter 4 demonstrated that the
formulation is generally applicable to hydrophobic small molecules and that SPARC is involved
in the cellular uptake of Abxtal formulations.
In Chapter 5, the potential utility of nanoparticles in immune checkpoint blockade therapy
was discussed. The limitations of immune checkpoint blockade therapy may be addressed by using
nanoparticles to enhance immunogenicity of tumor: (i) increasing tumor delivery of
chemotherapeutics that induce immunogenic cell death; (ii) altering cellular uptake mechanism
and consequent changes in the intracellular stress; (iii) creating, binding and retaining neo-antigens
in situ on the nanoparticle surface for efficient delivery to antigen presenting cells; and (iv) codelivery of immune adjuvant.

6.2

Perspectives on NP-based drug delivery
As discussed in Chapter 1, even ideal nanoparticle-based systems will not work well in the

patient population without the EPR effect (e.g. poorly vascularized tumor). Therefore,
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nanoparticle-based drug delivery systems should be developed and pursued in a personalized
manner: specific subset of patients who manifest favorable tumor physiology need to be identified
prior to the nanoparticle treatment to maximize the clinical benefit of nanoparticle-based systems.
With understanding of heterogeneity and complexity of the EPR effect and optimally designed
nanoparticles, nanoparticle-based systemic delivery of chemotherapeutic is feasible for clinical
translation.
In addition, the role of nanoparticles should not be limited as a drug delivery carrier. As
discussed in Chapter 5, nanoparticles may function as a carrier of neo-antigens and synergize with
immune checkpoint blockade therapy. “Re-purposing” approach has good potential for clinical
translation and commercialization, because the modalities are already available in the clinics.

116

APPENDIX A. SUPPLEMENTARY FIGURES

Supplementary Figure 1. (a) Size of Cim-F-alb as a function of hydration time (n=9 for >15 min
hydration and n=3 for 5 min and 5 sec hydration). (b) TEM images of Cim-F-alb prepared with
>15 min hydration (left) or 5 sec hydration (right). (c) Dissolution rate of Cim-F-alb (eq. to PTX
2 μg/mL) prepared with 15 min hydration (black) or 5 sec (red) in PBS containing 0.2%
Tween80.

Supplementary Figure 2. Particle size of Cim-F-alb freeze dried with different trehalose/Cim-Falb w/w ratio and reconstituted in water.
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Supplementary Figure 3. (a) PTX and protein contents in each PTX NC formulation, determined
by HPLC and SDS-PAGE, respectively. n = 4 independently and identically performed
experiments. (b) Zeta potential of NC, measured in phosphate buffer (pH 7.4, 1 mM). n = 3
independently and identically performed experiments. *: p<0.05 by Tukey’s multiple
comparisons test.

Supplementary Figure 4. NC-bound protein bands in SDS-PAGE gel were identified by LCMS/MS. Briefly, the Coomassie stained bands were excised from the gel and destained by
washing with a 50:50 mixture of 25 mM ammonium bicarbonate (ABC; pH 8.5) and ACN for 4
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times. The gel was dried with vacuum centrifuge and treated with 10 mM dithiothreitol (DTT)
for 1 h at 55˚C to reduce cysteines. After DTT was removed, 55 mM iodoacetamide (IAA) was
added to alkylate cysteines for 45 min, followed by washing with a 50:50 mixture of 25 Mm
ABC and ACN for 3 times. Lys-C/trypsin was added to cover each gel piece and incubated in
barocycler at 50˚C (120 cycles of 20 kpsi for 50 seconds and atmospheric pressure for 10 sec) for
digestion. Peptides from gel pieces were extracted by adding 60% ACN/5% trifluoroacetic acid
(TFA) with sonication, and the dry peptide pellet was resuspended in 94.9% water, 3% ACN,
0.1% formic acid (FA). The samples were run on a nano Eksigent 425 HPLC system coupled to
the Triple TOF 5600 plus (Sciex, Framingham, MA). The peptides were loaded onto a Sciex
NanoLC Chrom XP C18 trap column (350 μm x 0.5 mm) for concentration, and this enrichment
column was switched to the nano flow path after 5 min. Peptides were separated using the
reversed phase 3C18-CL C18 analytical column (75 μm x 150 mm) from Sciex. The sample was
injected into the Triple TOF 5600 plus through the Nanospray III source fitted with an emission
tip from New Objective. Peptides from the digestion were eluted from the columns using a
mobile phase A (0.1% formic acid in H2O) and a mobile phase B (0.1% formic acid in ACN).
With a flow rate of 300 nL/min, the method began at 95% A for 1 min followed by a gradient of
5% B to 35% B in 61 min and from 35% B to 80% B in 1 min. 80% B was held for 6 min, then
brought to 5% B, and held for 20 min. Data acquisition was performed monitoring 50 precursors
at an accumulation time of 250 ms/scan. Database searches of the UniProt_human proteins were
performed using Mascot Daemon v.2.5.1 (Matrix Science) with peptide mass tolerance of 0.05
Da and fragment mass tolerance of 0.2 Da. The false discovery rate (FDR) was adjusted to 5%.
Among the identified proteins, proteins with (i) no relevance (e.g. keratin), (ii) molecular weight
with much discrepancy with one estimated from gel, (iii) Mascot protein score below the 5%
confidence threshold, and (iv) exponentially modified protein abundance index (emPAI), an
estimation of protein abundance, less than 1.0 were excluded. The selected proteins were
matched to the identified proteins from albumin stock solution.

Supplementary Figure 5. PTX uptake by J774A.1 macrophages after 3h incubation at 37 °C with
Cim-F and Cim-F-alb (equivalent to 30 μg/mL PTX) in serum containing media. n= 3 replicates.
*: p<0.01 by two-tailed unpaired t-test.
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Supplementary Figure 6. (a) Cytotoxicity of Pluronic F127 in B16F10 cells after 3h exposure,
measured by MTT assay (n=3 measurements). (b) Cytotoxicity of PNC-alb, Cim-F-alb, and a mixture
of PNC-alb and 10 μg/mL F127 in B16F10 cells after 3 h exposure, measured by MTT assay (n=3
measurements). *: p<0.01 by Tukey’s multiple comparisons test.
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Supplementary Figure 7. Fluorescence intensity of Rhodamine B at different pH’s.
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Supplementary Figure 8. TEM images of Cim-F-alb and RhoB-labeled Cim*-F-alb.

Supplementary Figure 9.Intracellular localization of rhodamine B doped Cim*-F-alb (Top) or
Oregon green-conjugated Cim#-F-alb (bottom) in B16F10 cells after 30 min incubation.
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Supplementary Figure 10. Intracellular localization of RhoB doped Cim*-F-alb in B16F10 cells
after 30 min incubation at 37 ˚C or 4 ˚C. Scale bar: 10 μm.
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Supplementary Figure 11. Assessment of colocalization of Cim*-F-alb with Lysotracker. The degree
of colocalization was analyzed by using Coloc 2 plugin of ImageJ. Pearson’s correlation coefficient
(R) represents the degree of colocalization: R=1 (perfect colocalization), R=0 (no colocalization), R=1 (perfect exclusion).
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Supplementary Figure 12. Supporting Figure 12. X-ray diffraction patterns of as-received PTX.
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Supplementary Figure 13. X-ray powder diffraction patterns of Abraxane and Cim-F-alb.

124

Supplementary Figure 14. Cytotoxicity of Cim-F-alb, Abraxane, and free PTX in SKOV-3 human
ovarian cancer cells measured by MTT assay (n=4 measurements) and B16F10 melanoma cells
measured by PI staining and flow cytometry (n=2 independently and identically performed
experiments) and MTT assay (n=3 measurements) varying the post-treatment incubation time
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Supplementary Figure 15. All images of TUNEL-stained B16F10 tumor sections. Two randomly
selected fields were imaged for each animal in the PBS, Abraxane and Cim-F-alb treatment groups
(n=6 for PBS, Abraxane; n=7 for Cim-F-alb).
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Supplementary Figure 16. TUNEL stained B16F10 tumor section at high magnification indicating
co-localization of TUNEL signal and nuclei stain.
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Supplementary Figure 17. Weight change of healthy C57BL/6 mice receiving Cim-F-alb in
different doses. C57BL/6 mice received Cim-F-alb every 3 days five times via tail vein injection
at doses equivalent to PTX 15 (n=1), 30 (n=3), 60 (n=3), or 90 mg/kg (n=3). Mice with body
weight loss in excess of 20% were sacrificed. Arrows indicate the times of treatment.

Supplementary Figure 18. Recovery of protein corona bound to PNC and Cim-F-alb with multiple
washing. PNC and Cim-F-alb were incubated in mouse serum for 15 min and washed up to 3
times. After each washing step (0, 1, 2, and 3 times), PNC and Cim-F-alb were analyzed by
SDS-PAGE to profile protein corona.
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Supplementary Figure 19. Characterization of NCs with and without pre-formed corona (PC). Zaverage (with PDI) and zeta potential of PNC and Cim-F-alb were obtained before (PNC, Cim-F-alb)
and after 15 min incubation in mouse serum followed by twice washing with PBS (PNC/PC, Cim-Falb/PC). The measurements were made in 1 mM sodium phosphate buffer (pH 7.4).
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Supplementary Figure 20. Protein corona on NCs analyzed by SDS-PAGE. (Top) PNC, Cim-C-alb,
and Cim-F-alb were incubated in mouse serum for 15 min or 3 h. Estimated molecular weight and
relative quantity of protein bands in gels were presented as a heatmap. Each NC sample was
separated by vertical black lines (n=5 for PNC and Cim-F-alb; n=3 for Cim-C-alb). (Bottom)
All SDS-PAGE images: Lane1= PNC15min, 2 = Cim-F-alb15min, 3 = Cim-C-alb15min, 4 = PNC3h,
5 = Cim-F-alb3h, and 6= Cim-C-alb3h. Subscripts (15min and 3h) indicate the time of incubation
in serum.
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Supplementary Figure 21. Stability of PNC in PBS and serum. Derived count rate of PNC in (a) PBS
and (b) undiluted FBS at 37 ˚C. The baseline derived count rate of FBS at each time point was
subtracted from the values of PNC suspensions in FBS. The linear relationship between
derived count rate (absolute scattering intensity) and NC concentration (the number of
particles) indicate the stability of NCs.
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Supplementary Figure 22. Anti-tumor activity of Abraxane, Cim-F-alb, and PNC at PTX 30 mg/kg
q3d × 5. Abraxane (blue; n=6), Cim-F-alb (red; n=6), or PNC (green; n=6). (a) Dosing schedule.
(b) Changes of individual B16F10 tumor volume. Arrows indicate the times of treatment. (c)
Body weight change of treated mice. (d) Kaplan–Meier survival curve. (e) Specific growth
rate of B16F10 tumor. ΔlogV/Δt (V: tumor volumes; t: time in days). *: p<0.05 by Dunn’s
multiple comparisons test.
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APPENDIX B. SUPPLEMENTARY TABLES

Supplementary Table 1. Maximum tolerated doses (MTD) of commercial paclitaxel formulations
in mouse models.
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Supplementary Table 2. Blood chemistry parameters in mice used for MTD determination
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Supplementary Table 3. Kinetic parameters of NC binding to serum protein-coated biosensor via
BLI
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